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Abstract 
Protein engineering can be made far more powerful if a protein is not only expressed 
recombinantly but also altered covalently using synthetic chemistry. These two methods 
are brought together in the protein semi-synthesis technique Expressed Protein Ligation 
(EPL). In EPL, recombinant and synthetic polypeptides are joined together via a 
chemoselective ligation reaction. EPL was originally used to attach synthetic constructs 
to the C-terminus of recombinant proteins, but is now used to attach recombinant or 
synthetic polypeptides either at the N- or C-terminus of a protein or into the core of a 
protein. This thesis illustrates, with three distinct applications, the development of EPL 
from its original definition to its current understanding. In the first application, a general 
strategy was developed for the site-specific incorporation of fluorophores into proteins 
using Abl-SH3 as a model system. In the second application, chemistries were developed 
that allowed the site-specific introduction of phospho-amino acids into proteins, in this 
case using the transforming growth factor p receptor I as the model system. In the final 
application, EPL was used to synthesize several modified versions of the E. coli sigma 
factor o70, demonstrating that this method can be used to probe extremely large 
macromolecules. These studies revealed that EPL works under a variety of reaction 
conditions and provided paradigms for using this technique to site-specifically insert 
fluorophores and phosphate groups into proteins. The chemical manipulation of proteins 
by EPL will be an important tool as researchers strive to characterize the proteomes of 
organisms. 
Chapter 1: Introduction 
"The name protein which I propose to you for the organic oxide of fibrin and of albumin, 
I wanted to derive it from Kpcoxetot, [in the lead] because it seems to be the original 
or principal substance of animal nutrition. " 
~G. J. Mulder (Soderbaum, 1916). 
Importance of proteins 
Proteins have achieved what most rock bands struggle to obtain: to go from a 
small unknown to world-renowned recognition that spans the test of time. When G. J. 
Mulder first coined the phrase 'protein' in 1838, it was used to represent a poorly defined 
conglomeration of atoms. At the time, organic chemists busied themselves trying to 
analyze the components of proteins, from the point of view that they were derived from 
plants and passed onto human beings through consumption of animal and plant products 
(Tanford, 2001). Since that time it has been well established that proteins in the body are 
not derived from nutrition, but rather are manufactured as gene products. The completion 
of the human genome, in addition to the genomes of several other organisms, has 
heralded the protein molecule to super star status. 
With the genetic blueprint of several organisms now available, a new challenge 
has emerged. Namely, the characterization of many of tens of thousands of novel gene 
products at the chemical and biological levels. Often referred to as the 'proteome 
project,' this is an enormously daunting undertaking, particularly given the emerging 
picture of complexity in biological processes, where proteins are involved in the 
everyday "molecular business of biology" (Jones, 1994). In order to fully comprehend a 
biological process, one must understand at a fundamental level the role proteins play. 
Consequently, this requires access to proteins, and the ability to manipulate them. In this 
instance, access refers to the capability of obtaining workable amounts of protein, and 
manipulation is the ability to design and construct proteins endowed with the probes 
appropriate for the process under investigation. As a direct response to this need, the 
field of protein engineering has developed several methods for manufacturing peptides 
and proteins through the use of protein engineering techniques that encompass the purely 
synthetic (Jackson et al., 1994) and the purely biosynthetic (Chang et al, 1994) (Offer, 
2000). However, before continuing the discussion on proteins, it is necessary to take a 
step back and discuss the proteins' junior counterpart peptides. For it is from the field of 
peptide synthesis that initial stabs at protein engineering were made. 
Evolution of peptide synthesis 
The field of peptide synthesis began with the contributions of Theodore Curtis 
and Emil Fischer. In 1881 Curtis was the first to synthesize a protected peptide (Curtius, 
1881), then, in 1901, Fischer was the first to synthesize an unprotected dipeptide 
(Fischer, 1901). In the hundred years since these founding endeavors the field of peptide 
synthesis has achieved astounding progress (Figure 1.1). Each mark in the timeline 
shown in Figure 1.1 represents a hurdle peptide chemists had to overcome in order to 
attempt to reproduce nature's accuracy and efficiency in a synthetic form. 
-100-
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Y E A R 
Figure 1-1.100 years of chemical peptide synthesis. A plot depicting the achievements 
of the field of peptide synthesis over the past 100 years. 
The first of these hurdles was to devise a method for reacting amino acids. Due to 
the zwitteronic nature of amino acids, two amino acids will not react on their own to form 
a peptide bond. To initiate the formation of a peptide bond an activating agent, called a 
"coupling agent," has to be added to the mixture. The initial coupling agents used were 
devised by the founding fathers and involved activating the carboxyl group of an amino 
acid to nucleophilic attack. Activation is achieved by replacing the hydroxyl of the 
carboxylic acid with an electron withdrawing group, thus increasing the electrophilicity 
of the carboxyl group. Curtius utilized an acid azide coupling method, where he 
activated the carboxyl group of an amino acid by converting it to an acid azide (Curtius, 
1881). Fischer devised the acid chloride method, activating the carboxyl group by 
replacing the hydroxyl function with a chloride atom (Fischer, 1901). 
The knowledge of how to react two amino acids did not immediately result in the 
efficient synthesis of peptides. Both Curtius's and Fischer's methods had significant 
drawbacks which made the task of engineering a peptide extremely laborious. 
Specifically, Curtius's method is limited by the tendency of the acid azide to rearrange to 
the isocyanate, this is known as the Curtius rearrangement. With Fischer's method the 
acid chloride rearranges to a highly reactive amino acid derivative, N-carboxyanhydride, 
which is unsuitable for peptide synthesis due to instability and loss of chiral integrity. 
Such difficulties were due in part to the fact that there was not an efficient method for 
reversibly protecting the "amino group of an amino acid. Bergman and Zervas solved the 
problem in 1932 when they introduced the benzyloxycarbonyl (Z) group (Bergmann, 
1932). The Z group is a urethane protecting group that is readily removed by 
hydrogenolysis or acidolysis (Figure 1.2A). Bergman and Zervas's innovation was three 
fold. First, it presented an easy solution to the problem of reversibly protecting the 
"amino group, as hydrogenolysis and acidolysis were techniques that were well 
established at the time. Second, it served as the basis for which all modern day "amino 
protecting groups are designed, namely, urethane protecting groups. Thirdly, it prevented 
racemization. Up to this point racemization of amino acids was a persistent obstacle, thus 
it greatly advanced the field to discover that N" protection of amino acids by urethane 
derivatives essentially eliminated the problem. The Z group was the first of a series of 
pivotal developments that provided the infrastructure for peptide synthesis as it is known 
today. 
What followed were new, more efficient coupling agents to replace Curtius and 
Fischer's methods, namely amino acid anhydrides (Wieland, 1951) and active esters 
(Bodanszky, 1955; Wieland, 1951). Also, Bergman and Zervas's urethane protecting 
group strategy was greatly improved with the introduction of the tertiary 
butyloxycarbonyl (Boc) and 9-fluorenylmethoxycarbonyl (Fmoc) groups (Carpino, 
1957), which could be removed by milder acidic conditions than the Z group (Figure 1.2 
B & C ) . 
•V 
HN R 
/ HF ^ < 
\ , H2/Pd 
A ^ J 
+ o= + R NH3*F 
Removal of the Z group 
./" 
TFA 
+ o= + R NH3*CF3COCr 
Removal of the Boc group 
+ o= + R Nhfc 
Removal of the Fmoc group 
Figure 1-2. Removal of urethane Na protecting groups. (A) Removal of Z-group, (B) 
Removal of Boc group, (C) Removal of the Fmoc group. Both the Boc and Fmoc groups 
are removed under milder conditions as compared to the hydrogenolysis or strong acid 
treatments of the Z group. 
When Merrifield introduced the Solid Phase Peptide Synthesis (SPPS) method in 
1963, he harvested the previous advances and introduced an innovation that changed the 
field forever (Merrifield, 1963). Up to that point peptide synthesis was done in the 
solution phase, with the most memorable contribution made by Du Vigneaud in 1953 
when he synthesized the octapeptide Oxytocin (du Vigneaud, 1953). One major 
drawback to solution phase synthesis is that it is very labor intensive. This is due to the 
fact that each step in the synthesis has to be purified to get rid of excess activated amino 
acid required to optimize each coupling. Merrifield simplified the process by using an 
insoluble polymer support to anchor the peptide as it was being synthesized (Figure 1.3). 
Figure 1-3. Schematic of Merrifield's Solid Phase Synthesis Strategy (SPPS). Dark 
circles and triangles depict side chain and N"- protecting groups, respectively. At each 
step a protected amino acid is attached to the growing peptide chain that is connected to a 
resin support. The final step is removal of the peptide chain from the resin support to 
yield the free peptide. 
The anchoring of the amino acids residues as they are sequentially elongated 
made it extremely easy to wash away excess material, purifying the reaction in a manner 
of minutes versus hours with the solution phase approach. In his book, Life during the 
Golden Age of Peptide Synthesis. Merrifield describes his approach and the advantages it 
would have over solution phase methods (Merrifield, 1993): 
One day in 1959 I had an idea about how we might 
synthesize peptides in a simpler, faster, and more efficient 
way then could be done by the classical methods. The idea 
was to make use of an insoluble solid support to hold the 
peptide chain while it was being assembled. The plan was 
to begin with some stable insoluble polymeric material that 
could be derivatized with a functional group through which 
the terminal amino acid residue of the peptide chain could 
be attached. The next residue would be suitably protected 
and then activated and coupled to the first one to form the 
peptide bond. A repetition of the process would yield the 
tripeptide, and so on until the desired peptide sequence was 
assembled. Removal of protecting groups and cleavage 
from the insoluble support would then yield the final 
peptide. The expected advantage of this approach was the 
ability to filter the mixture after each reaction and remove 
the excess soluble reagents and by products. The solid 
support and the growing peptide that was covalently 
attached to it would remain on the filter. In principle, all 
the reactions could be performed in a single reaction vessel, 
and higher yields and fewer losses of material could be 
expected... Because the reagents were in solution but the 
peptide chain was in the solid phase, I gave the technique 
the name 'solid -phase peptide synthesis.' 
Merrifield's accomplishments, coupled with those of Sheehan (carbodiimide 
activation) (Sheehan, 1955), Carprino (Boc, Fmoc protecting groups) (Carpino, 1957), 
Konig and Geiger (HOBt activation) (Konig, 1970), Sheppard (Fmoc SPPS) (Atherton, 
1978), and other's paved the way for the efficient synthesis of longer and longer peptide 
chains. Several proteins were prepared by SPPS (Akaji, 1985; Sieber, 1978; Zawadzke, 
1993), the most memorable being the HIV-1 protease that led to the crystal structure of 
the protein (Miller et al., 1989; Schneider and Kent, 1988). But this success was limited, 
usually requiring large teams and taking years to complete. By the 1990's modern 
improvements in the SPPS method made the synthesis of peptide fragments up to 50 
amino acids in length a routine and reliable process (Kiso, 1990; Schnolzer, 1992; Tarn, 
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1983), but there are very few proteins that are 50 amino acids long. The logical next step 
was to find a way to link the peptide chains together, in essence, to synthesize big 
polypeptides or proteins. 
Evolution of chemical protein synthesis 
When Emil Fischer synthesized the first free dipeptide in 1902, it was with the 
intention of one day being able to synthesize an enzyme. He wrote: 
M y entire yearning is directed toward the first synthetic 
enzyme. If its preparation falls within m y lap with the 
synthesis of a natural protein material, I will consider m y 
mission fulfilled (Fruton, 1985). 
For eight years, 1902-1910, Fischer tried to synthesis an enzyme. In 1910, 
frustrated that his mission would not be fulfilled, Fischer terminated all peptide synthesis 
work in his laboratory. He cited the limitations of his synthetic methods as the reason. 
Many years later peptide chemists would take up the protein synthesis torch again. This 
time equipped with far superior synthesis methods than those available to Fischer. 
However, due to the sheer scale of the problem (proteins being significantly larger than 
peptides) modern day peptide chemists would find the challenge just as daunting as 
Fischer did. 
Merrifield and others had succeeded in making peptide synthesis extremely 
successful and efficient, to the point where eventually it was automated. The next 
obvious step would be to apply the techniques learned in peptide synthesis to chemical 
protein synthesis. Unfortunately, the two fields are not so readily integrated. Not only 
are proteins much larger than peptides, they also have higher dimensions of organization 
that have to be accounted for. As polypeptide chains increase in size they start to acquire 
secondary and eventually tertiary structure. The formation of these structures make SPPS 
synthesize of large proteins almost impossible, as they decrease the efficiency of the 
coupling reactions that lead to chain elongation. A logical solution to this problem was to 
make smaller peptide fragments and link them together in a convergent approach. 
The initial fragment condensation approach to synthesizing proteins called for 
small protected peptide segments of the protein of interest to be first constructed using 
SPPS, then chemically linked together in solution to produce the target sequence. 
Fragment condensation of peptide chains exploits the advantages of SPPS, as peptide 
fragments up to 50 amino acids were becoming readily available. However the 
disadvantage of this method is similar to that of classic solution phase peptide synthesis, 
namely, in order to prevent branching of the peptide or undesired chain assembly, it is 
necessary to protect the reactive side-chain functionalities of each fragment. Protected 
peptide fragments are difficult to purify, characterize, and tend to have solubility 
problems. Despite these problems the total chemical synthesis of proteins via fragment 
condensation has enjoyed significant successes. The syntheses of insulin (Sieber, 1978), 
Rnase A (Akaji, 1985), human PTH (Tarn, 1986), and human EGF (Heath, 1988) serve to 
illustrate this point (reviewed in (Lloyd-Williams et al., 1993)). 
Several influential contributions have been made in an effort to solve the 
problems associated with the classic fragment condensation approach. These include the 
thiol-capture strategy of Kemp (Kemp and Carey, 1993), which relies on a proximity-
based entropic activation step, and the minimal protected fragment condensation 
approaches of Blake and Yamashiro (Blake and CM., 1981; Yamashiro and Li, 1988), 
which utilizes peptide "thioacid derivatives. However, it was not until the emergence of 
the chemical ligation approach that the problems of classic fragment condensation were 
significantly addressed. The conceptual breakthrough at the heart of the chemical 
ligation approach is the realization that a synthetic protein need not only contain amide 
linkages within its polypeptide backbone. Accordingly, chemical ligation strategies 
utilize alternative organic reactions all of which, initially, generated non-amide linkages 
between the peptides being joined together. Thioester (Schnolzer, 1992; Williams, 1994) 
and hydrazone (Gaertner, 1992) forming reactions were among the first to be described, 
but have since been joined by oxime (Rose, 1994), thioether (Muir, 1994; Nefzi et al., 
1995) and thiozolidine (Liu and Tam, 1994) (Figure 1.4). All chemical ligation strategies 
rely on highly selective reactions between synthetic peptide fragments, each bearing 
unique and mutually reactive groups. The chemoselective nature of the chemical ligation 
method means that fully unprotected peptide segments can be used. 
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These chemical ligation strategies have allowed synthetic and, in some instances, 
recombinant polypeptides to be joined together through non-native linkages (for reviews 
see (Dawson, 2000; Muir, 1995; Wallace, 1995)). 
The field of chemical ligation was revolutionized by the efforts of Steve Kent and 
colleagues with the advent of Native Chemical Ligation (Dawson et al, 1994). In native 
chemical ligation, as with other chemical ligation strategies, two fully unprotected 
synthetic peptide fragments are chemically ligated under neutral aqueous conditions, but 
unlike other ligation strategies, native chemical ligation results in the formation of a 
native peptide bond at the ligation site. A s illustrated in Figure 1.5A, native chemical 
ligation involves the chemoselective reaction between a peptide fragment containing a 
"thioester and another peptide fragment containing an N-terminal cysteine residue. The 
initial transthioesterification reaction is followed by a rapid intramolecular S->N acyl 
shift to generate an amide bond at the ligation junction. Accordingly, the target full-
length polypeptide is obtained in the desired final form without further manipulation. 
Native chemical ligation can be performed in the presence of all the functionalities 
commonly found in proteins, including free cysteine sulfhydryls. This is because 
cysteine residues that are not at the N-terminus cannot spontaneously rearrange to give an 
amide bond, and due to the reversible nature of the initial transthioesterification step, are 
simply converted back to starting materials. This advantage has made native chemical 
ligation the most successful and commonly used chemical ligation approach to be utilized 
in the synthesis of proteins with an average size of 100 amino acid residues (Baca et al., 
1995; Dawson et al, 1997; Muir et ah, 1997; Tarn, 1995) (for review (Dawson, 2000)). 
Native chemical ligation increases by two fold the size of peptides that can be made by 
SPPS. However, in order to break the size barrier and synthesize larger proteins, it is 
necessary to broaden the scope of chemical protein synthesis beyond peptide chemistry. 
Protein semi-synthesis is an elegant chemistry driven approach to engineering 
proteins that involves a multidisciplinary cast of characters from biologists to organic 
chemists. With semi-synthetic approaches scientists meet nature halfway and effectively 
eliminate the "size issue" in chemical protein synthesis. If scientists surrender 
completely to nature, heterologous expression of recombinantly cloned genes is by far the 
most efficient route to engineered proteins. Site-directed mutagenesis is facilitated by the 
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"replicative fidelity and efficiency of living organisms (Woods et al., 1996)," a property 
which also constrains the approach to the naturally occurring amino acids. Protein semi-
synthesis surmounts the limitation of recombinant expression by allowing for the 
incorporation of unnatural amino acids into proteins. 
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Figure 1-5. Mechanism of (A) Native Chemical Ligation, (B) Protein Splicing, (C) 
Expressed Protein Ligation. 
The term "protein semi-synthesis" originally referred to processes in which 
proteolytic or chemical cleavage fragments of natural proteins were used as the building 
blocks for the resynthesis of the protein (reviewed in (Wallace, 1995)). For example, it 
was noted nearly 30 years ago that CNBr fragments of pancreatic trypsin inhibitor 
spontaneously condense to reform the native peptide bond between them, an effect that is 
also observed with cytochrome c (Wallace and Clark-Lewis, 1992). In both cases, the 
two fragments produced after CNBr cleavage cooperatively refold, bringing the 
homoserine lactone at the carboxy-terminus of one fragment in close proximity to the 
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free amino terminus of the other. This autocatalytic fragment religation approach, termed 
confirmationally assisted protein synthesis, has been used to incorporate natural and 
unnatural amino acids into cytochrome c (Wallace and Clark-Lewis, 1992). 
Another general approach to protein semi-synthesis involves the use of proteolytic 
enzymes to facilitate the regioselective ligation of peptide fragments. Classically, this 
"enzyme-assisted reverse proteolysis" strategy involved altering the reaction conditions 
such that aminolysis of an acyl-enzyme intermediate is favored over hydrolysis. This is 
typically achieved by including high concentrations of organic solvents such as glycerol, 
D M F , or acetonitrile in the reaction medium (Homandberg, 1978). Significant progress 
in the area of enzyme-assisted reverse proteolysis has been achieved by genetically 
engineering the active site of the proteolytic enzyme. This approach was pioneered in the 
mid 1980's by Kaiser and co-workers who chemically incorporated a thiol group into the 
active site of the serine protease subtilisin. The resulting thiol subtilisin analog possessed 
improved acylation activity relative to the wild-type enzyme (Nakatsuka et al., 1987). In 
an extremely elegant extension of this work, Wells and co-workers have further 
engineered subtilisin affording an enzyme capable of efficiently catalyzing the ligation of 
peptide fragments (Jackson et al., 1994). Their double mutant form of the enzyme, 
termed subtiligase, functions as an effective acyl transferase and importantly has vastly 
reduced proteolytic activity compared to the wild-type enzyme. Mutation of the active 
site serine to a cysteine allows the enzyme to be acylated with peptides esterified at their 
C-terminus with a glycolate phenylalanyl amide ester group. A second active site 
mutation (proline to alanine) relieves steric crowding, allowing efficient aminolysis of the 
enzyme-peptide thioester intermediate by the amino-terminus of a second peptide 
fragment. Subtiligase has been used to prepare totally synthetic proteins (Jackson et ah, 
1994) and semi-synthetic proteins (Chang et al, 1994). 
Semi-synthesis techniques like conformationally assisted protein synthesis 
(Wallace and Clark-Lewis, 1992), enzyme-assisted reverse proteolysis (Jackson et al, 
1994; Nakatsuka et al, 1987), and unnatural amino acid mutagenesis (Cornish et al, 
1995) have been successfully applied to the construction of proteins with unnatural 
probes. The methods listed above have provided researchers with a chemical toolbox for 
manipulating proteins in order to investigate biological processes. However, there is a 
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dilemma in that not too many researchers are equipped to access the toolbox. For 
example, in Schultz's unnatural amino acid mutagenesis, the ribosomal machinery is 
essentially tricked into incorporating the desired unnatural amino acid into the protein by 
mutating the codon of interest with an amber codon. The mutant gene is then added to an 
in vitro translation mix containing semi-synthetic suppressor tRNA charged with the 
unnatural residue. Although highly innovative (having been used to introduce a range of 
unnatural amino acids into proteins such as lysozyme and ras p21), unnatural amino acid 
mutagenesis is labor intensive, technically demanding, and often results in a low yield of 
the desired protein. If we were to construct a plot of the evolution of protein semi-
synthesis similar to that constructed for peptide synthesis in Figure 1.1, where instead of 
size on the Y-axis we plotted utility or accessibility of approach, one would find that not 
many researchers are using the protein semi-synthesis techniques that are currently 
available. Expressed protein ligation (EPL), a novel protein semi-synthesis tool 
developed in the Muir lab in 1997, combines recombinant biology and synthetic 
chemistry in a way that promises to make proteins containing unnatural building blocks 
accessible to most researchers (Evans et al, 1998; Muir et al, 1998; Severinov and Muir, 
1998)(xeview (Holford, 1998)). 
Development of Expressed Protein Ligation 
Expressed protein ligation, is a protein semi-synthesis method that developed 
from the unexpected convergence of two, at first glance, unrelated areas of research; 
protein total synthesis (Dawson, 2000; Kent, 1988) and protein self-splicing (Perler et 
al, 1997). EPL was developed to address some of the limitations of earlier chemical 
protein synthesis approaches, such as the size of proteins synthesized, and accessibility of 
the techniques. At the core of the EPL technique is the chemical synthesis method native 
chemical ligation. As described above, native chemical ligation is a technique where the 
chemoselective reaction of a C-terminal thioester and an N-terminal cysteine yields a 
native peptide bond at the site of ligation (Figure 1.5A.). The two reactive moieties 
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necessary for native chemical ligation to occur, an N-terminal cysteine and a C-terminal 
"thioester, are also necessary for EPL to occur. 
As originally noted by Kent and co-workers (Dawson et al, 1994) and later 
demonstrated with chimeric heterodimers of the transcription factors c-Jun and c-Fos 
(Erlandson et al, 1996), the N-terminal Cysteine moiety may be generated via 
recombinant D N A methods. Most approaches currently in use for preparing N-terminal 
cystein proteins involve the in vitro use of exogenous proteases. In the approach 
developed by Verdine and co-workers, a factor Xa recognition sequence is appended 
immediately in front of the cryptic N-terminal cysteine in the protein of interest 
(Erlandson et al, 1996). Treatment of this recombinant fusion protein with the protease 
gives the requisite N-terminal cysteine protein directly, which can then be used in 
subsequent ligation reactions (Erlandson et al, 1996; Huse, 2000; Xu et al, 1999) 
(demonstrated in section 3.2). Tolbert and Wong recently showed that the cysteine 
protease from tobacco etch virus (TEV) can also be used to release N-terminal cysteine 
proteins from suitable precursors (Tolbert, 2002). The ability to produce N-terminal 
cysteine moieties via recombinant technology has a two fold effect: first, it eliminates the 
size constraints of C-terminal fragments used in native chemical ligation, and 
subsequently EPL thus, expanding the chemical protein engineering tool box. Second, 
recombinant D N A technology is a technique that is readily attainable by most 
researchers, and therefore it broadens the appeal of the approach. 
Though N-terminal cysteines could be obtained recombinantly, "thioesters were 
not as readily accessible. The solution to this problem was obtained with the discovery of 
the protein splicing phenomenon. 
Protein splicing is a post-translational process by which an intervening sequence, 
termed an intein, is removed from a host protein, termed an extein (Perler et al, 1994). 
The first intein was discovered in 1990 as a 'spacer' within the Saccharomyces cerevisiae 
vascuolar ATPase (See V M A ) gene that was absent in other V M A homologues (Hirata, 
1990; Kane et al, 1990). Since then, over 100 putative inteins have been identified and 
catalogued in InBase, the online intein registry and database 
nittpAwww.neb.com/neb/inteins.html) (Perler, 1999). Intein-mediated protein splicing 
is the protein equivalent of R N A splicing. However, unlike R N A splicing, which 
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requires the help of an elaborate ribonuclear protein complex, protein splicing is an 
intrinsic process, and can take place in vitro using purified pro-proteins (Xu and Perler, 
1996). This has allowed the mechanism of intein-mediated splicing to be studied in some 
detail using both mutagenesis and protein chemistry based techniques (Chong et al, 
1996; Shao et al, 1996; Xu and Perler, 1996) (for review see (Perler, 2000)). 
The conventional mechanism of protein splicing (alternative mechanisms have 
been identified (Southworth, 2000) is summarized in Figure 1-5B. The initial step in the 
mechanism is an N->S or N->0 acyl shift, where the amino terminal peptide bond of 
Seri or Cysl is replaced with a (thio)ester bond. This initial step in the protein splicing 
mechanism is essentially the reverse of the final step in native chemical ligation, 
(compare Figure 1.5 A and B). The N->S or N->0 acyl shift appears to be energetically 
unfavorable and the driving force(s) behind this event is still the subject of study. 
Although, crystal structures of several inteins have been solved (Duan et al, 1997; Hall, 
1997; Hashimoto, 2000; Ichiyanagi, 2000; Klabunde et al, 1998; Poland, 2000), there is 
still a question as to why the first step in the mechanism occurs. In the crystal structure 
determined by Sacchettini and co-workers of the GyrA intein, the amide bond between 
the final residue in the N-extein and the first residue in the intein is observed to be in the 
higher energy cw-conformation. It is possible that this unusual stereochemical constraint 
helps push the equilibrium of the system towards the (thio)ester side. 
After the initial N->(S,0) rearrangement, a trans-esterification reaction occurs, 
moving the N-extein from the side chain of the first residue in the intein to the side chain 
of the first residue in the C-extein, which is always a Ser, Thr or Cys. This step results in 
ligation of the exteins and formation of a branched protein intermediate. In the next step, 
the amide bond at the intein-C-extein junction is broken as a result of succinimide 
formation involving the conserved C-terminal asparagine residue within the intein. In the 
final step of the process, a peptide bond is formed between the N-extein and C-extein 
following an (S,0)->N acyl shift; identical to the final step in native chemical ligation. 
The uncanny chemical similarities between native chemical ligation (Figure 1-
5A) and protein splicing (Figure 1-5B) raised the question: is it possible to use protein 
splicing as a route to recombinant protein "thioesters for use in native chemical ligation? 
The answer to this question was demonstrated by Xu and co-workers with the discovery 
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that protein splicing can be halted at the first step of splicing, presumably at the (thio) 
ester intermediate stage by mutation of the key asparagine residue in the intein to an 
alanine (Chong et al, 1997). Proteins expressed as in-frame amino-terminal fusions to a 
mutated intein can be cleaved by thiols via an intermolecular trans-thioesterification 
reaction to generate a recombinant protein "thioester derivative. The recombinant 
"thioester can then be reacted with a polypeptide containing an amino-terminal cysteine 
via native chemical ligation. E .coli expression vectors are now commercially available 
which allow the generation of protein fusions to two different engineered inteins, the 
Saccharomyces cerevisiae vacuolar ATPase (See V M A ) intein and the Mycobacterium 
xenopi D N A gyrase A (Mxe GyrA) intein. 
The stage was thus set for the genesis of a new protein semi-synthesis approach 
that would pull together protein splicing and native chemical ligation. This new method, 
termed Expressed Protein Ligation, initially, allowed synthetic peptides to be chemically 
ligated to the C-terminus of recombinant proteins through a native peptide bond (Evans et 
al, 1998; Muir et al, 1998; Severinov and Muir, 1998; Holford, 1998;). The mechanism 
of EPL is shown in Figure 1-5C. In the first step, the protein fragment of interest is 
expressed as an intein-affinity tag fusion, where the affinity tag allows the protein of 
interest to be purified. By using an engineered intein, protein splicing is unable to 
proceed to completion and is stalled at the stage involving the thioester-linked 
intermediate (Figure 1-5B, step 1). Consequently, exposure of the immobilized fusion 
protein to an aqueous solution containing an N-terminal cysteine peptide and a catalytic 
thiol reagent result in native chemical ligation of the peptide to the protein. The final 
product is an engineered protein that includes a synthetic fragment via which unnatural 
probes may be introduced. 
The three initial works of EPL each used the mechanism shown in Figure 1-5C. 
Namely, EPL was used to attach synthetic peptides to the C-terminus of recombinant 
proteins. However, since its inception in 1997 (the year I joined the Muir lab), the goal 
of EPL has been to expand to include the addition of not only synthetic fragments, but 
also recombinant fragments, to either the N or C-termini, or to insert fragments into the 
core of a protein, see Figure 1-6. Such attributes would make EPL a useful tool for the 
researchers involved in the proteome project. As mention before, the proteome project is 
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daunting and will require a collective effort from diverse branches of science. Everyone 
from applied physicists to zebra fish biologists will have an input deciphering the vast 
amount of proteins. This varied congregation will need tools that can extend across 
traditional barrier lines. Expressed protein ligation has the ability to be that kind of tool. 
At its origin E P L encompasses scientific collaboration (synthetic chemistry and protein 
splicing). In this thesis alone, E P L has facilitated the joining of peptide/protein chemists 
with structural and molecular biologists. The objectives of this thesis helped to 
characterize many of the early underlying breakthroughs that have significantly aided in 
advancing E P L to a technique that is each day gaining ground with different investigators 
and being used in innovating ways to address questions from protein folding to cell 
signaling (for reviews (Hofmann, 2002; Muir, 2001)). 
A. N-terminal Ligation. 
N 
Synthetic or recombinant fragment 
recombinant protein 
B. C-terminal Ligation. 
N 
C. Protein Insertion. 
Figurel-6. Envisioned E P L protein synthesis strategies. Three different possibilities 
for combining recombinant proteins with synthetic or recombinant fragments: (A) C-
terminal ligation. The fragment is attached to the C-terminus of the recombinant protein. 
(B) N-terminal ligation. The fragment is attached to the N-terminus of the recombinant 
protein. (C) Protein insertion. Insertion of the fragment into the core of the protein. 
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Objectives of thesis 
The overall goal of this thesis is to illustrate the development and application of 
the protein semi-synthesis technique expressed protein ligation as a readily accessible and 
effective tool for the incorporation of unnatural amino acids and physical probes into 
proteins. Specifically, E P L was applied to the incorporation of fluorophores, post-
translational modifications, and U V photochemical cross-linkers into proteins of 
biological interest. 
The scope and versatility of the expressed protein ligation method was 
demonstrated using three distinct applications. In the first application, a strategy was 
developed for the site-specific incorporation of fluorophores into large proteins. Using 
the Src homology 3 (SH3) domain of the Abelson protein tyrosine kinase (Abl) as a 
model system, a method was be developed for the incorporation of fluorophores into so 
called contiguous receptor-ligands, designed to act as biosensors for macromolecular 
interactions. With the second application, a general strategy was developed to introduce 
site-specific post-translational modifications into proteins for analysis of signal 
transduction. This strategy was applied to the selective phosphorylation of the 
transforming growth factor (3 receptor I (TJ3R-I) G S region to investigate the role 
phosphorylation plays in the receptor's signaling activities. To this end, an approach was 
developed for the synthesis of phosphorylated thioester peptides for use in E P L reactions. 
The final application calls the for design and synthesis of several modified versions of the 
E. coli sigma factor, a70, in order to investigate inhibition of the protein. Using EPL, a 
general technique was developed for incorporating U V photochemical cross-linkers and 
fluorophores into modified versions of a70, which was used in a variety of experiments to 
investigate h o w a70 is inhibited by the bacteriophage T4 anti-sigma (AsiA) protein. 
The goal of this thesis was achieved through a synergy of the existing methods 
(native chemical ligation, protein splicing, recombinant biology) and novel techniques 
(expressed protein ligation) that, when used in conjunction, provide unique opportunities 
for expanding the boundaries of protein engineering. 
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Chapter 2: Materials and Methods 
"Great things are not done by impulse, but by a series of small things brought together. " 
- V a n G o g h (1853-1890) 
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2.1 General Reagents and Methods 
Solid-phase peptide synthesis. 
Boc-amino acids were obtained from Novabiochem (San Diego, CA), Bachem (Torrance, 
C A ) or Neosystems (France). HBTU, and 4-methylbenzylhydrylamine ( M B H A ) resin 
were obtained from Richelieu Biotechnologies (Montreal, Canada), and Peninsula 
Laboratories (Belmont, CA), respectively. JV.AT-Dimethylformamide and HPLC-grade 
acetonitrile was purchased from Fischer. Trifluoroacetic acid was purchased from 
Halocarbon (River Edge, NJ). HF was purchased from Matheson Gas. All other reagents 
were obtained from Aldrich Chemical Co. All polypeptides were manually synthesized 
according to the in situ neutralization/HBTU activation protocols for Boc SPPS 
(Schnolzer, 1992) on a M B H A resin. Global deprotection and cleavage from the support 
was achieved by the treatment with hydrogen fluoride (HF) containing 5 % (v/v) p-cxesol, 
for one hour at 0° C. Following the removal of HF, crude peptide products were 
precipitated and washed with anhydrous cold Et20 before being dissolved in degassed 
aqueous acetonitrile (50%) and lyophilized. Polypeptides were purified by preparative 
H P L C and in all cases, polypeptide composition and purity were confirmed by E S M S and 
analytical HPLC. 
Reverse phase HPLC. 
Analytical H P L C were preformed on a Hewlett-Packard 1100 series instrument with 
diode array detection. Analytical runs were performed on a reversed-phase Vydac C18 
column (5 micron, 4.6 m m x 150 m m ) at a flow rate 1 mL/minute. Preparative H P L C 
was performed on a Waters DeltaPrep 4000 system fitted with a Waters 486 tunable 
absorbance detector using a Vydac C18 column (15-20 micron, 50 m m x 250 m m ) at a 
flow rate of 30 mL/minute. All runs used linear gradients of 0.1% (w/v) aqueous TFA 
(solvent A) versus 9 0 % (v/v) acetonitrile plus 0.1% TFA (solvent B). 
22 
M a s s spectrometry. 
Electrospray mass spectrometry (ESMS) was routinely applied to all synthetic peptides 
and components of reaction mixtures. E S M S was performed on a Sciex API-100 single 
quadrupole electrospray mass spectrometer. Matrix-assisted laser desorption ionization 
(MALDI) mass spectrometry was performed on a Perseptive Biosystems Voyager-DE 
STR Biospectrometry Workstation and analyzed using the m/z program. Calculated 
masses were obtained using the program MacProMass (Sunil Vemuri & Terry Lee, City 
of Hope, Duarte, CA). 
2.2 Materials and Methods used in Section 3.1 
Synthesis of H2N-LysIRhl-(Gly)n-(3BP2)-Ahx-Arg-Ala-Lys[Fl]-CONH2 (1). 
The peptide was synthesized (0.1 mmole scale) on a M B H A resin using a Boc/Bzl 
protection strategy. Orthogonal protection of the lysine e-NH2 groups with 
fluorenylmethoxycarbonyl allowed directed attachment of the tetramethylrhodamine and 
fluorescein groups (activated as .TV-hydroxysuccinimide esters) before the final cleavage 
step. Following cleavage, the peptide (140 mg) was purified by preparative RP-HPLC 
using a linear gradient of 25-40% B over 60 min to give 15 m g (0.04 mmole, 8 % yield) 
of material. The purified peptide was characterized as the desired product (1) by E S M S 
[observed mass = 3024.32 ± 0.8 Da; expected mass (average isotopic mass) = 3025.0 
Da]. 
Synthesis of Cys-Abl-SH3 (2). 
Synthesis of the 57 amino acid peptide (residues Leu65- Val119of native sequence) [NH2-
C L F V A L Y D F V A S G D N T L S I T K G E K L R V L G Y N H N G E W B E A Q T K N G Q G W V P 
SNYITPVN-COOH] was preformed on a 0.5 mmole scale on an Asn-Pam resin. The 
naturally occurring Cys101 in wild-type Abl-SH3 was mutated to a-aminobutyric acid (B) 
to avoid side reactions during thioether ligation. Following HF cleavage (400 mg), the 
peptide was purified by preparative RP-HPLC using a linear gradient of 35-45%B over 
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60 min. The purified peptide was characterized by E S M S [observed mass = 6302.58 ± 
0.75 Da; expected mass average isotopic mass) = 6301.8 Da]. 
Synthesis of N-iodoacetylated 3BP2 peptide (IAc-3BP2) (3). 
In a 1 m L eppendorf, 4 m g of purified (1) was solubilized in 800 m L of 8 M urea, 100 
m M 2-[N-Morpholino]ethanesulfonic acid (MES) pH= 6.3. Iodoacetic anhydride 
solution was prepared by dissolving 5.28 m g of iodoacetic anhydride in 200 ml of 
tertahydrofuran (THF). 21 m L (1.5 mmol) of iodoacetic anhydride solution was then 
added to the eppendorf containing the solubilized peptide (1). The reaction was allowed 
to proceed for 30 min then the desired N-iodoacetylated 3BP2 peptide (LA.C-3BP2) (3) 
was purified by semi-preparative RP-HPLC using a 25-45% B linear gradient over 60 
min. The purified product was characterized by E S M S [observed mass = 3191.6 + 0.1 
Da; expected mass (average isotopic mass) = 3192.0 Da]. 
Synthesis of Abl-SH3-3BP2 FRET biosensor using thioether approach (4). 
2.5 m g (0.8 jimol) of IAc-3BP2 (3) and 12.5 m g (1.9 \xmol) of Cys-Abl-SH3 (2) were 
solubilized in 1 m L of degassed 8 M urea, 0.1M sodium phosphate buffer pH 7.4. The 
reaction proceeded for 1 hour then the reaction was purified by semi-preparative RP-
H P L C using a 30-55% B linear gradient over 60 min. The purified product (4) was 
characterized by E M S [observed mass = 9370.0 + 0.8 Da; expected (average isoptopic 
mass = 9368.1 Da]. 
Preparation of Recombinant Abl-SH3-Intein-CBD (5). 
E. coli BL21 cells transformed with pTYB2Abl-SH3 (Xu et al, 1999) were grown to 
mid-log phase in Luria Bertani (LB) medium and induced with 0.1 m M IPTG at room 
temperature for two hours to yield protein in the soluble fraction. Following 
centrifugation, cells were re-suspended in 60 ml of lysis buffer (25 m M HEPES, pH 8.0, 
0.1 m M EDTA, 250 m M NaCl, 5 % glycerol, 1.0 m M PMSF) and lysed using a French 
press. The lysate was clarified by centrifugation and then loaded onto a 15 ml chitin 
column pre-equilibrated in column buffer (20 m M HEPES, pH 7.0, 250 m M NaCl, I m M 
EDTA, 0.1% Triton X-100), the column was extensively washed using the same buffer 
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and then stored at 4°C until further use. The loading of the column was determined by 
cleavage of 100 -uL of beads in ligation buffer (0.2 M phosphate, 0.2 M NaCl, pH 7.2) 
containing 100 m M DTT. The amount of cleaved protein in solution was quantified by 
analytical RP-HPLC by comparison to a stock solution of known concentration. This 
afforded a resin loading of 0.4 mg/mL. 
Synthesis of Cys-3BP2 (6). 
The peptide was synthesized as described for peptide (1) with chain elongation continued 
to include an N-terminal cysteine residue. The purified peptide was characterized by 
E S M S [observed mass = 3128.1 + 0.8 Da; expected mass (average isotopic mass) = 
3129.5 Da]. 
Semi-synthesis of Abl-SH3-3BP2 FRET biosensor by EPL (7). 
Purified peptide (6) (1.0 mg) was dissolved in 2.0 ml of ligation buffer containing 1 0 % 
(v/v) D M S O . The solubilized peptide was added to 1.5 ml of Abl-SH3-Intein-CBD (5) 
chitin beads in the presence of 1.5 % (v/v) thiophenol. The ligation reaction was allowed 
to proceed for 44 hours at room temperature with gentle mixing, at which point the 
desired ligation product (7) was purified by semi-preparative RP-HPLC using a linear 
gradient of 25-50% B over 1 hour to yield 0.7 mg (74 nmole, 7 7 % yield) of material. 
The purified product was characterized by E S M S [observed mass = 9371.2 ± 0.8 Da; 
expected mass (average isotopic mass) = 9370.5 Da]. 
Synthesis of NH2-Cys-Gly-Arg-Gly-Arg-Gly-Arg-Lys[Fll-CONH2 (8). 
The peptide was synthesized (0.5 mmole scale) on an M B H A resin using a Boc/Bzl 
protection strategy. Orthogonal protection of the lysine e-NH2 group with 
fluorenylmethoxycarbonyl allowed specific attachment of the fluorescein moiety 
(activated as iV-hydroxysuccinimide ester) before the final HF cleavage step. The 
cleaved peptide was purified by preparative RP-HPLC using a linear gradient of 0-73% B 
over 60 min to give 25 m g (0.02 mmole, 52%) of material. The purified peptide was 
characterized by E S M S [observed mass = 1245.9 ± 0.1 Da; expected mass (average 
isotopic mass) = 1246.5 Da]. 
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Model E P L Studies Between Abl-SH3-Intein-CBD (5) and peptide (8). 
Peptide (8) was dissolved (1 mg/mL) in a ligation buffer containing either 0, 2, 3,4 or 5.5 
M GdmCl (final concentration after dilution effect of the beads). This solution (100-200 
pX) was then added to typically 50-100 pX of Abl-SH3-intein-CBD beads (5) 
equilibrated in ligation buffer and either 1 % thiophenol (v/v) or 1 % 2-
mercaptoethanesulfonic acid (w/v) added to the mixture. The ligation reaction was 
allowed to proceed at room temperature overnight with gentle agitation. The amount of 
ligation product Abl-SH3-Cys-Gly-Arg-Gly-Arg-Gly-Arg-Lys[Fl]-CONH2 (9), present at 
different time-points was determined by analyzing aliquots of the reaction supernatant by 
analytical RP-HPLC and ESMS: [observed mass 7488.0 ± 1.5 Da; expected for (9) 
(average isotope composition) = 7488.5 Da]. 
Synthesis of NH2-CNTDYLEEVGKQFDVTRERIRQIEAKALRKLRH-
CONH2(10). 
The peptide was synthesized (0.33 mmole scale) on a p-methylbenzhydrylamine resin 
using a Boc/Bzl protection strategy. Following cleavage (355 mg) and global 
deprotection with HF, the peptide was purified by preparative H P L C using a linear 
gradient of 30-60% B over 60 min to give 44 mg (0.011 mmole, 16% yield) of material. 
The purified peptide was characterized as the desired product (10) by E S M S [observed 
mass = 4115.9 ± 0.5 Da; expected mass (average isotopic mass) = 4117.7 Da]. 
Semi-synthesis of Abl-SH3-[CNTDYTLEEVGKQFDVTRERIRQIEAKALR 
K L R H - C O N H 2 ] using E P L (11). 
Purified peptide (10) (0.6 mg) was dissolved in 0.1 ml of ligation buffer containing 2 M 
GdmCl. The solubilized peptide was added to 100 nl of Abl-SH3-intein-CBD chitin 
beads (5) in the presence of 1.0 % (v/v) M E S N A . The ligation reaction was allowed to 
proceed for 24 hours at room temperature with gentle mixing, at which point the desired 
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ligation product was isolated by analytical H P L C and characterized by E S M S [observed 
mass = 10357.5 ± 2.0 Da; expected mass (average isotope comp. = 10358.3 Da). 
Synthesis of P40 (12) and NS (13) ligands. 
P40 (12) (APTYSPPPPP) was synthesized (0.5 mmole scale) on an MBHA resin using 
standard Boc SPPS. Following HF cleavage the peptide was purified by preparative 
reverse-phase H P L C using a linear gradient of 7-27% B over 60 min. The purified 
peptide was characterized as the desired product by E S M S [observed mass = 1022.9 + 
0.7 Da; expected mass (average isotopic mass) = 1023.2 Da]. N S (13) (YSPWTNF) was 
obtained from a co-worker in the lab. 
Fluorescence spectroscopy. 
Experiments were conducted at 18°C in a stirred 0.5 cm-path length cuvette using a 
SPEX FL3-1 IC fluorimeter. Excitation was at 490 nm with a 1.5 nm slit width and the 
fluorescence emission was monitored at 520 nm and 580 nm through a 5 n m slit. The 
protein was titrated with increasing concentrations of each ligand; P40 (12) or N S (13), 
and the change in the emission ratio of fluorescein to rhodamine (580:520) was 
monitored as a function of ligand concentration. In all cases, the protein concentration 
was kept at 50 n M in a buffer containing 150 m M NaCl, lOOmM sodium phosphate 
buffer pH 7.2. 
Circular dichroism spectroscopy. 
C D measurements were preformed on an Aviv 62DS spectropolarimeter at 25° C using a 
0.02cm path length cuvette. Protein concentrations were 50,uM in 150mM NaCl, lOOmM 
sodium phosphate buffer pH 7.2. Spectra were recorded from 250 to 190 n m using a step 
of 0.5 n m and an averaging time of four seconds. 
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2.3 Materials and Methods used in Section 3.2 
Synthesis of Na-Biotin-GTTLKDLIYDMTTSGSGSGLPL-COS-propion-
amide (GS-OBio (14)). 
The peptide was synthesized (0.03 mmole scale) on an (MBHA) resin (Camarero, 1998) 
according to the in-situ neutralization/HBTU activation protocol for Boc SPPS, and the 
N-terminus of the peptide was biotinylated using biotin N-hydroxysuccinimide. 
Following chain assembly, global deprotection and cleavage from the support was 
achieved by treatment with HF containing 4 % (v/v) p-cresol, for 1 h at 0°C. Following 
removal of the HF, the crude peptide product was precipitated and washed with 
anhydrous cold Etf) before being dissolved in degassed aqueous acetonitrile (50% B) 
and lyophilized. The crude peptide (20 mg, 7.87 nmole) was purified by semi-
preparative H P L C using a linear gradient of 35-45% B over 60 min to give 4 m g (1.6 
p.mole, 2 0 % yield) of material. The purified peptide was characterized as the desired 
product (GS-OBio) (14) by E S M S [observed mass = 2542.2 ±0.1 Da; expected mass 
(average isotopic mass) = 2540.7 Da]. 
Synthesis of H2N-TTLKDLIYDMpTTpSGpSGpSGLPL-COS-Bzl (GS-4 
(15)). 
The peptide was synthesized (0.3 mmole scale) on a sulfamylbutyryl A M resin using the 
Fmoc N" SPPS strategy. The C-terminal leucine residue was loaded onto the resin using 
the method of Backes et al. (Backes, 1999), which afforded an initial loading of 0.3 
mmole/g. All amino acids (2.2 mmole) were coupled using H B T U activation with the 
exception of Fmoc-Ser(PO(OBzl)OH)-OH and Fmoc-Thr(PO(OBzl)OH)-OH which were 
coupled using PyBOP as the activating agent. Coupling times ranged from 1-2 hours, 
and all residues from Metl84-pSer191 of GS175"195 were double coupled. The N-terminal 
Thr was attached as a Boc-Thr(OtBu)-OH derivative. Following chain assembly, the 
peptide resin was activated by an overnight reaction with ICH2CN (9.5 mmole) in D M F 
(3.2 m L ) in the presence of DIEA (220 mL). Iodoacetonitrile used for N-alkylation was 
prefiltered through an basic alumina plug. After extensive washing with D M F and D C M , 
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a portion (600 mg, 0.075 mmole) of this resin was treated with BzlSH:DIEA:DCM (2.7 
m L : 1 m L : 17.8 m L ) for 6 hours at room temperature with gentle stirring at which point 
the slurry was concentrated in vacuo. Global deprotection was then achieved by treating 
the dried resin with 25 m L TFA containing 5 % H20 (v/v) and 5 % p-cresol (v/v) as 
scavengers. Following removal of the TFA in vacuo, the crude peptide product was 
precipitated and washed with anhydrous cold EtjO before being dissolved in degassed 
aqueous acetonitrile (50% B) and lyophilized. The crude peptide (117 mg, 0.045 mmole) 
was purified by semi-preparative H P L C at 50°C using a linear gradient of 35-45% B over 
60 min to give 6 m g of purified GS-4 (15) (2.3 mmole, 5.1% yield) of material. W e 
attributed the modest yield of GS-4 (IS) to 1) to incomplete thiolysis of the peptide from 
the resin, confirmed by amino acid analysis of the resin after cleavage, and 2) incomplete 
deprotection of the phosphate groups, confirmed by E S M S of the primary contaminant, 
which displayed an additional 90 Da. The purified peptide was characterized as the 
desired product (15) by E S M S [observed mass = 2597.0 ± 0.5 Da; expected mass 
(average isotopic mass) = 2596.5 Da]. 
GSATfJR-I (16) Expression and Purification (performed by M. Huse). 
Expression 
In general, followed the protocols found in the Bac-To-Bac™ baculovirus expression 
system manual (Gibco BRL) to produce recombinant T0R-I protein. The Leu196-Cys 
mutation and the coding sequence for Factor Xa cleavage (IEGR) were encoded in the N-
terminal primer used to amplify the GSATbR-I (16) D N A fragment. The D N A was 
cloned into the pFastBacHTa expression vector (Gibco BRL) using the Spel and SphI 
restriction endonuclease sites. This strategy placed the Factor Xa cleavage site and 
GSAT^R-I (16) coding sequence downstream of a hexahistidine tag. For expression, 4-6 
liters of confluent SF9 cells in suspension culture (~2 X IO6 cells/mL) were infected with 
GSAT^R-I (16) baculovirus at a multiplicity of infection of 1-10 virus particles per cell. 
Cells were harvested after 50 hours and washed in PBS before being frozen at -78°C. 
Purification 
4-6 liters of frozen, GSAT|3R-I (16) expressing SF9 cells were thawed and resuspended in 
70 m L of 20 m M Tris pH 8.5, 10 m M 0-mercaptoethanol (p*-ME), 8 % glycerol (v/v), and 
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1 m M phenyl-methyl sulphonyl fluoride (PMSF). The cells were lysed by sonication and 
the resultant lysate subjected to centrifugation at 16,500 rpm in a midspeed Beckman J2-
M I centrifuge for 1 hour. The soluble fraction of the lysate was filtered through a syringe 
filter with a 5 u,m pore size (Nalgene). The sample was then applied to a large Q 
sepharose column (~50 m L bed volume; Pharmacia) equilibrated in a buffer containing 
20 m M Tris pH 8.5, 5 m M 0-ME, 8 % glycerol (v/v). Under these conditions, the His-
tagged GSAT^R-I (16) protein elutes isocratically immediately following the flow 
through peak. Fractions containing GSAT0R-I (16) were confirmed by SDS-PAGE and 
pooled for Ni2+ affinity purification. NaCl and imidazole were added to the protein at this 
stage to final concentrations of 500 m M and 15 m M , respectively. The sample was then 
applied to a 15 m L Ni2+-NTA column (Qiagen) equilibrated with a buffer containing 20 
m M Tris pH 8.5, 5 m M 0-ME, 15 m M imidazole, 500 m M NaCl, and 8 % glycerol (v/v). 
The column was washed and the salt concentration reduced to 50 m M by a linear gradient 
into a buffer containing 20 m M Tris pH 8.5, 5 m M |3-ME, 15 m M imidazole, 50 m M 
NaCl, 8 % glycerol (v/v). The protein was then eluted with a linear gradient into a buffer 
containing 20 m M Tris pH 8.5, 5 m M 0-ME, 1 M imidazole, 50 m M NaCl, 8 % glycerol 
(v/v). Fractions containing His-tagged GSAT|3R-I (16) were pooled and the approximate 
concentration of the sample assessed by an absorbance measurement at 280 nm. The 
His-tag was then removed by Factor Xa digestion in the presence of 2 m M dithiothreitol 
(DTT). Note, factor Xa cleaves G S ATP R-I (16) nonspecifically in the absence of 
reducing agent. 15 units of factor Xa were added for every mg of GSAT0R-I (16), and 
the digestion was allowed to proceed at room temperature for 7 hours at which point 1 
m M P M S F was added to quench the reaction. The cleaved GSAT^R-I (16) protein was 
subsequently purified from the protease using an A T P sepharose affinity column 
(prepared as described in (Huse, 2000)). The ATP column was equilibrated with a buffer 
containing 20 m M Tris pH 8.5, 10 m M MgCl2, 2 m M DTT, 8 % glycerol (v/v). Prior to 
loading, MgCl2 was added to the sample to a final concentration of 10 m M . After 
loading, the column was washed with a buffer containing 20 m M Hepes pH 8.0, 2 m M 
DTT, 8 % glycerol (v/v), and then eluted with a linear gradient into a buffer containing 20 
m M Hepes pH 8.0, 1 M NaCl, 5 m M EDTA, 2 m M DTT, 8 % glycerol (v/v). The 
purified protein was characterized as the desired product (16) by E S M S [observed mass = 
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35,263 ±11.8 Da; expected mass (average isotopic mass) = 35259.6 Da]. Pure GSATpR-
I (16) protein was concentrated using a 15 m L Biomax ultrafiltration device (Millipore) 
with a 30 kD molecular weight cutoff to a final concentration of 0.1 m M . 
mercaptoethanesulfonic acid ( M E S N A ) and hepes pH 8.0 were added to final 
concentrations of 50 m M and 100 m M , respectively, and the protein solution was flash 
frozen in 100 pX aliquots. GSATpR-I (16) was stored at -78°C until further use. 
Synthesis of GS-OBioTpR-I (17) and GS-4T0R-I (18) by EPL. 
In general, ligation reactions were initiated by dissolving purified peptide (100 nmol) in a 
100 m L aliquot of purified GSAT0R-I (16) (10 nmol protein). For GS-4 ligations, the 
protein solution was brought to 1 M NaCl and 0.1 m M Na3 VO4 prior to the addition of 
the peptide. Vanadate was added to inhibit any phosphatase activity that may have 
copurified with GSAT|3R-I (16), and the higher salt concentration reduced GSATJ3R-I 
(16) aggregation. Ligation reactions were performed at 4°C, and their progress monitored 
by SDS-PAGE. GS-OBio reactions were generally stopped after 10-12 hours, GS-4 
reactions after 24-48 hours. Reactions were stopped by gel filtration, which separated the 
protein components from the unreacted peptide. Gel filtration was performed using a 
Superdex 75 H R 10/30 column equilibrated in 20 m M hepes pH 8.0, 500 m M NaCl, 2 
m M DTT, 8 % glycerol (v/v). There are three major peaks observed by H P L C analysis of 
in T[3R-I ligation reactions, a peak at the void volume consisting of aggregated protein, a 
second peak corresponding to monomeric protein, and a third peak of unreacted peptide. 
The second peak is enriched in ligation product, and was, in both cases, the sample used 
for subsequent purification. 
GS-0BioTpR-I (17) Purification. 
GS-0BioTPR-I (17) was purified from unreacted GSAT0R-I (16) using monomeric 
avidin agarose affinity beads (Pierce). Avidin agarose (1 m L ) was placed in a gravity 
flow column and equilibrated in the following equilibration buffer: 20 m M Tris pH 7.5, 
150 m M NaCl, 4 m M DTT. After sample loading, the column was washed with 
equilibration buffer and eluted with a buffer containing 20 m M Tris pH 7.5, 150 m M 
NaCl, 2 m M biotin, 4 m M DTT. The elution fractions containing GS-OBioT0R-I (17) 
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were pooled and then concentrated by ultrafiltation using a centricon 30 (Millipore). The 
protein was concentrated to ~1 mg/mL. GS-OBioTbR-I (17) may be stored indefinitely at 
-78°C. The identity of GS-OBioTbR-I (17) was confirmed by E S M S [observed mass = 
37698.0 ± 7.2 Da; expected mass (average isotopic mass) = 37695.2 Da]. 
GS-4T0R-I (18) Purification. 
GS-4T0R-I (17) was purified from unreacted GSAT0R-I (16) by anion exchange 
chromatography using a 1 m L Resource Q column (Pharmacia). The column was 
equilibrated in a buffer containing 20 m M Tris pH 8.5, 2 m M DTT, 8 % glycerol (v/v) 
and eluted with a linear gradient into a buffer containing 20 m M Tris pH 8.5, 1 M NaCl, 
2 m M DTT, 8 % glycerol (v/v). The sample was diluted 5 fold in equilibration buffer 
prior to loading. Most of the unreacted GSAT0R-I (16) flows through the column under 
these conditions. The eluted fractions containing GS-4T|3R-I (18) were pooled and then 
concentrated by ultrafiltation using a centricon 30 (Millipore). The protein was 
concentrated to ~2 mg/ml and can also be stored indefinitely at -78°C. GS-4T(3R-I (18) 
does not ionize under electrospray conditions (presumably a consequence of the 4 
phosphates in the protein), but can be observed using MALDI-MS [observed mass = 
37,731 ± 18 Da; expected mass (average isotopic mass) = 37,731.9 Da]. 
In Vitro Kinase Assays (performed by M. Huse). 
The relative concentrations of the T|3R-I fragments used in this assay were determined by 
H P L C peak integration and referenced to T^R-Icyt, whose concentration had been 
determined previously by absorbance at 280 nm. Kinase reactions were performed in a 
buffer containing 50 m M Tris pH 7.5, 60 m M NaCl, 5 m M MgCl2, 5 m M MnCl2, 2 m M 
DTT, 0.1 m M Na3V04. Kinase activity is barely detectable in the absence of MnCl2. 
While this requirement for Mn2+ is not fully understood, it is not unusual for kinases to 
require ions other than Mg2+ for full activity (Amrein, 1995; Herrera, 1988). The 
substrate used in these assays is a complex between the C-terminal Smad2 M H 2 domain 
and the 85 residue Smad binding domain of the Smad Anchor for Receptor Activation 
(SARA). S A R A stabilizes Smad2, and renders it more soluble. The appropriate T(3R-I 
fragment (10 pmole) and Smad2/SARA complex (80 pmole) were used in each reaction. 
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The total reaction volume was 15 mL. Reactions were initiated by the addition of A T P 
(200 m M final concentration) along with 7.5 mCi of [y-32P]ATP (Pharmacia), and were 
allowed to proceed at room temperature. They were quenched after 10 min by the 
addition of 5 m L SDS-PAGE sample buffer. Samples were subjected to SDS-PAGE, and 
the incorporation of radioactivity into each protein visualized and quantitated using a 
Storm 840 phosphorimager (Molecular Dynamics). All quantitated assays were 
performed in triplicate. T0R-Icyt and Smad2/SARA were expressed and purified as 
described previously (Huse, 1999; W u , 2000). 
2.4 Materials and Methods used in section 3.3 
Synthesis of a70 4.2 benzophenone cross-linker peptides (19-25). 
All derivatized peptides were synthesized on a 0.1 mmol scale using Boc SPPS. During 
the synthesis, a single Boc-Dapa(Fmoc)-OH amino acid was incorporated at positions 
corresponding to o amino acids 571 (20), 578 (21), 586 (22), 588 (23), 593 (24) or 597 
(25). After the synthesis was complete, each Dapa(Fmoc)-containing peptide was treated 
with 2 % D B U , 2 0 % piperidine in D M F (3 x 5minute). The free P-amino group was then 
acylated (2 x lhour) with p-benzoyl-benzoic acid (52.6mg, 0.23mmol) activated as its 
symmetrical anhydride using DIC (0.11 mmol, 15 \i\) in D M F (3mL). After the second 
coupling the acylation reaction was > 99 % complete, as judged by ninhydrin. The 
peptide-resins were cleaved and deprotected by treatment with anhydrous HF, and the 
derivatized peptides were purified by H P L C using a linear gradient of 35-55% B. 
Peptide composition and purity were confirmed by analytical H P L C and E S M S (see 
Table 1 for masses). 
Cloning and expression of AsiA protein. 
The AsiA protein used in cross-linking experiments was obtained from Leonid Minakhin. 
The details of the cloning and expression are published (Minakhin, 2001). 
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U V Photo Cross-Linking Experiments. 
Each cross-linking reaction contained, in 15 nl of transcription buffer (50 m M Tris-HCl, 
pH 7.9, 10 m M MgCl2, 40 m M KCI, 1 m M p-mercaptoethanol) 200 pmol of AsiA and 3 
nmol of derivatized a70 region 4.2 peptide. Reactions were incubated for 5 min at 37 °C 
and irradiated 20 times with 5-7 ns pulses of UV-laser (YAC Powerlite 7000, 
Continuum) at 355nm, 50 mJ per pulse. Reaction products were analyzed by SDS P A G E 
(Tris-glycine 10-20% gradient, Bio-Rad) and visualized by Coomassie blue staining. 
Cloning and Expression of a70 constructs: a70i_566-VMA-intein-CBD (26) and 
a70ioi-566-VMA-intein-CBD (27). 
The constructs o7Y566-VMA-intein-CBD (26) and a70ioi-566-VMA-intein-CBD (27) were 
cloned and expressed in a manner similar to that described by Severinov et.al (Severinov 
and Muir, 1998). The plasmid pCYB2-o7Y566, which expresses regions 1 through region 
4.1 of a70 fused to VMA-intein-CBD from a trc promoter, was constructed by polymerase 
chain reaction amplification of the corresponding fragment of rpoD and recloning it in 
Ndel-Smal-treated plasmid pCYB2 (New England Biolabs) as previously described 
(Severinov and Muir, 1998). The D N A encoding a70i0i-566 was isolated by PCR using the 
pTYB2 plasmid as a template. The 5' primer (5'-GCG TCT A G A A A T A A T TTT G T T 
T A A G A A G G A G A T A T A C A T A T G T A C A T G C G T G A A A T G G G C A C C G-3') 
and the 3' primer (5'- G C G C G C G G T A C C C T T G G C A A A G C A C A T A T C G A T 
A C C G A A A C G C A T A C G C -3') encoded Xbal and Kpnl restriction sites, 
respectively. The P C R product was purified, digested simultaneously with Xbal and 
Kpnl and then ligated into the Xbal-KpnI-treated plasmid pTYB2 (New England 
Biolabs). The resulting pCYB2-o7Y566 and pTYB2-o70ioi-566 plasmids were shown to be 
free of mutations in the a70 coding region by D N A sequencing. Six liters of E. coli 
BL21(DE3) cells containing the pCYB2-o7Y566 or pTYB2-a70ioi-566 plasmid were grown 
to mid-log phase (OD590 = 0.6) in Luria-Bertani medium, induced with I m M IPTG at 
37°C for 6 hours and harvested by centrifugation. Cells were resuspended in 0.1 m M 
E D T A , 1 m M PMSF, 30 m M sodium phosphate, 250 m M NaCl buffer at pH 7.6 
containing 5 % glycerol and lysed using a French press. The lysate was centrifuged at 
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14,000 rpm for 30 minutes. The clarified supernatant was incubated for one hour with 5 
m L chitin-beads (New England Biolabs), previously equilibrated in washing buffer (1 
m M EDTA, 1 m M PMSF, 30 m M sodium phosphate, 250 m M NaCl buffer at pH 7.2). 
The beads were extensively washed with washing buffer (5x10 m L ) and stored as a 5 0 % 
suspension in wash buffer at 4 °C until further use. The loading of the column was 
determined by desorbing the fusion protein from a small aliquot of chitin beads with PBS 
containing 8 M GdmCl and quantifying the protein by U V absorbtion (a70i-566 £280= 
38480 cm" mol" and a7(\oi-566 £280= 35920 cm'mol"1). This analysis indicated a loading 
of ~ 10 mg/mL for both constructs. 
Synthesis of fluorescently labeled a70 region 4.2 peptides (region 4.2-fl (28)) 
and (region 4.2-dansyl (29)). 
Synthesis of the fluorescently labeled a70 region 4.2 peptides was conducted using 200 
m g of stock a70 region 4.2 peptide mutated at a70 Lys578 that had been prepared for the 
cross-linking studies as described above. Each Dapa (Fmoc)-containing peptide was 
treated with 2 % D B U , 2 0 % piperidine in D M F (3 x 5minute). The free P-amino group 
was then acylated (1 x 2hour) with 100 m g (0.2 mmol) NHS-fluorescein or 120 m g (0.4 
mmol) dansyl chloride dissolved in D M F (3 m L ) and DIEA (100 mL). After coupling 
the acylation reaction was > 99 % complete, as judged by ninhydrin. The peptide-resins 
were cleaved and deprotected by treatment with anhydrous HF, and the fluorescently 
labeled peptides were purified by preparative H P L C using a linear gradient of 30-50% B 
(28) or 30-60% B (29) over 60 minutes. Peptide composition and purity were confirmed 
by analytical H P L C and E S M S [(28) observed mass = 4434.46 ± 1.0 Da; expected mass 
(average isotopic mass) = 4432 Da. (29) observed mass = 4307.52 + 0.17 Da; expected 
mass (average isotopic mass) = 4306.0 Da]. 
Synthesis of peptide CGRAKG- (model-fl (30)) and (model-dansyl (31)). 
C G R A K G was synthesized on 0.5 mmol scale using Boc SPPS. Orthogonal protection of 
the lysine 8-NH2 group with fluorenylmethoxycarbonyl allowed directed attachment of 
NHS-fluorescein or dansyl chloride in a manner similar to that described for a70 region 
4.2 peptides (28) and (29) described above. Following HF cleavage the model peptides 
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were purified by preparative H P L C using a linear gradient of 15-40% B over 60 minutes. 
Peptide composition and purity were confirmed by analytical H P L C and E S M S [(5) 
observed mass = 948.9 ± 3.46 Da; expected mass (average isotopic mass) = 950.0 Da. (4) 
observed mass = 823.9 ± 0.70 Da; expected mass (average isotopic mass) = 824.0 Da]. 
Synthesis of a70 constructs: a70US66-4.2-a (32), a701^66-4^-fl (33), (fVs*-^-
dansyl (34), o 7 < W m o d e l Fl (35), o"lu.S66-model Fl (36), a'V-stt-model 
dansyl (37) using E P L . 
In general purified peptide (28), (29), (30) or (31) (0.2 - 7.0 mg) was dissolved in buffer 
A (50:UL - 1 mL). The solubilized peptide was then flash diluted into EPL buffer (0.1M 
sodium phosphate, 0.1M NaCl pH = 7.2) (200 |xL - 4 mL). The dissolved peptide was 
added to a 5 0 % slurry of a70 VMA-intein fusion protein (26) or (27) (200 p,L - 4 m L ) in 
the presence of 3 % ETSH and 100 m M mercaptoethanesulfonic acid (MESNA). The 
ligation reaction proceeded over night at room temperature with gentle mixing, at which 
point the ligation mixture was separated by centrifugation. The ligation supernatant and 
chitin beads were analyzed by SDS-PAGE electrophoresis and visualized by fluorescent 
imaging and coomassie staining. Characterization of the ligation supernatant by 
analytical H P L C and MALDI-TOF M S confirmed the desired a70 ligation product (32), 
(33), (35) and (36) (See Table 3 for masses) [(32) observed mass = 69,112 ± 86.6 Da; 
expected mass (average isotopic mass) = 69,178.1 Da. (33) observed mass = 58,258.2 + 
1.8 Da; expected mass (average isotopic mass) = 58,261.2 Da. (35)observed mass = 
65,730 ± 42 Da; expected mass (average isotopic mass) = 65,696.1 Da. (36) observed 
mass = 54,886.2 ± 97.4 Da; expected mass (average isotopic mass) = 54,799.2 Da]. 
Note, (34)and (37) did not ionize under MALDI-TOF M S conditions, but were 
confirmed by RP-HPLC and SDS-PAGE analysis. 
Purification of a70 ligation products. 
Ligation reaction supernatants were purified by anion exchange using a 1 m L Q 
sepharose HiTrap H P column (Amerhsham Pharmacia). The column was equilibrated in 
a buffer containing 0.1M NaCL, 30 m M sodium phosphate pH= 7.2 and eluted with a 
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linear gradient (flow rate 0.5 mL/min) into a buffer containing IM NaCl, 30 m M sodium 
phosphate pH 7.2 gradient. Most of the unreacted flourescently labeled region 4.2 (28 or 
29) flows through the column under these conditions. The eluted fractions containing the 
pure a70 constructs were then buffer exchanged into fluorescence buffer (0.1M sodium 
phosphate, 50 m M NaCl, pH = 7.2) using gel filtration with a Zorbax GF-250 column, 
running buffer 5 0 m M sodium phosphate, 0.1M NaCl pH = 7.2 over 17 minutes (flow rate 
1 mL/min). The fractions corresponding to the pure a70 constructs were analyzed for 
purity using MALDI- TOF M S and SDS-PAGE analysis. 
Fluorescence spectroscopy. 
Spectroscopic analysis of the a70 constructs was conducted at 25 C in a stirred 0.5 cm-
path length cuvette using a SPEX FL3-1 IC fluorimeter. Excitation was at 490 nm with a 
1.5 n m slit width and the fluorescence emission was monitored at 520 nm through a 5 n m 
slit. In all cases, the protein concentration was kept at 5 n M in fluorescence buffer. 
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Chapter 3: Results and Discussions 
"Luck is a large factor in the selection of a problem and the possibility that something 
new or unexpected will be found... In saying this, I realize how very lucky I have been-
chance was on my side. " 
—Bruce Merrifield in a discussion about the work that led to his Nobel Prize (Merrifield, 
1993). 
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3.1 Site-Specific Incorporation of Fluorescent Probes into Abl-SH3 
- 3 B P 2 Receptor-Ligand Complex 
Part of this work conducted in collaboration with Graham Cotton. 
Introduction to AM-SH3-3BP2 receptor-ligand complex - significance to E P L 
development 
The Src homology 3 (SH3) domains were initially identified as conserved 
sequences in the N-terminal non-catalytic regions of cytoplasmic tyrosine kinases, 
phospholipase C, and v C R K (Meyer, 1988). SH3 domains are found in a wide variety of 
proteins that are involved in several cellular functions including signal transduction (for 
review (Mayer, 2001; Pawson, 2002)). The Abl-SH3 domain was chosen as a model 
protein for the development of EPL for several reasons: it is well characterized both 
structurally and biochemically (Gosser et al, 1995; Musacchio et al, 1992; Musacchio et 
al, 1994; Pisabarro and Serrano, 1996), it is well behaved under normal physiological 
conditions and it can be reversibly unfolded (Xu et al, 1999). Also, the relatively small 
size of the Abl-SH3 domain, 57 residues, makes it well suited to analytical analysis 
methods like reverse-phase high performance liquid chromatography (RP-HPLC) and 
electrospray mass spectrometry (ESMS). Here the Abl-SH3 domain with its proline rich 
ligand 3BP2, was used as a model system to develop the tools that would allow for the 
site-specific incorporation of fluorophores into proteins using expressed protein ligation. 
In particular, an attempt was made to design a so-called contiguous receptor ligand 
biosensor for the Abl-SH3-3BP2 complex. Even though the efforts to manufacture a 
biosensor for the AM-SH3-3BP2 complex were unsuccessful, the semi-synthetic 
chemical synthesis of the complex illustrated the power of the EPL technique for site-
specifically incorporating fluorophores into proteins. Furthermore, model EPL studies 
with the Abl-SH3 domain indicated that ligations can be preformed in the presence of 
chaotropic and organic solvents. 
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Design of Abl-SH3-3BP2 contiguous- receptor ligand F R E T biosensor 
Biosensors can be the windows to the world of cell signaling (D' Auria, 2001; 
Tsien, 1998). They can provide the ability to study in vivo the molecular events that 
regulate signal transduction. A biosensor detects physical changes in the cell and, for 
example, combines these changes with a specific bimolecular ligand binding event. It is 
this unique action and reaction relationship that makes biosensors effective signaling 
tools. Fluorescent proteins that involve simply tagging a protein of interest with the 
Green Fluorescent Proteins (GFP) provide useful information on cellular localization but 
not necessarily functional information. A solution to this problem has been to engineer 
biosensors that integrate signal transduction functions, thereby tailoring the sensor to a 
particular mechanism. The problem with this strategy is that a different biosensor might 
be needed for every distinct signal transduction mechanism. Thus, an important goal is 
the design of a general protein ligand biosensor that is applicable to the majority of signal 
transduction mechanisms. 
In the quest for a general protein ligand biosensor design, the trend has been to 
exploit the ease of uv-visible spectroscopy to engineer biosensors with fluorescent probes 
(Czarnik, 1995; lmperali, 1998; Still, 1998; Taylor, 1995). Biosensing is achieved when 
ligand binding corresponds to a change in the fluorescence intensity by the fluorescent 
probe. In such a design it is important to distinguish between specific ligand binding and 
nonspecific interactions. As a potential solution to this problem the concept of a 
contiguous receptor ligand biosensor was introduced. A contiguous receptor ligand 
biosensor has a low affinity ligand attached to the receptor via an amino acid tether, such 
that it can assume an intramolecular association. As illustrated in figure 3.1-1, a 
contiguous receptor ligand biosensor provides a fluorescent signal only as a consequence 
of a specific biological interaction; nonspecific interactions do not elicit a signal. In 
designing the Abl-SH3-3BP2 biosensor, it was decided that the use of fluorescence 
resonance energy transfer (FRET) would allow spatial, as well as, functional information 
to be obtained from the biosensor. 
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-C02H 
(Gly)n ± Liaanc^ 
Ligand 
Figure 3.1-1. Concept of a contiguous receptor ligand biosensor. A change in ligand 
binding results in a change in fluorescence. 
FRET, initially described by Forester in 1940, is a process where nonradiative 
electronic energy is transferred from an excited fluorophore donor (D) to a fluorophore 
acceptor (A) (Forster, 1965; Forster, 1948) (for review (Dos Remedios, 1995)). The 
excitation reaction involved in the reaction is as follows: D* + A => D + A*. Where D* 
and A* indicate the excited states of the donor and acceptor, respectively. As the 
reaction proceeds the donor molecule becomes quenched and the acceptor molecule 
begins to fluoresce. Thus, FRET has an inherent mode of detection, which makes it ideal 
for application to biosensors and signal transduction. Several biosensors have been 
designed that utilize FRET (Cotton, 2000; Hofmann, 2001; Kurokawa, 2001; Miyawaki, 
1997). 
The intensity of FRET fluorescence is directly related to the spacing between 
donor and acceptor fluorophores. This is described by the following relationship: 
R=Ro(l/E-l)1/6 {equation 1} 
Where, R is the interchromophore distance between donor and acceptor, Ro, the Forster 
or critical transfer distance, is the distance between donor and acceptor when the 
efficiency of energy transfer is 50%, and E is the efficiency of energy transfer. Haugland 
and Stryer were the first to use FRET to calculate the distance between a fluorophore pair 
(Stryer, 1967). Using a napthyl group and a dansyl group as a donor and acceptor pair, 
they calculated the distance from N to C terminus of a 12 amino acid poly-proline 
peptide, demonstrating that FRET can be used as a "spectroscopic ruler," where changes 
in fluorophore distance results in a change in fluorescence. Consequently, if FRET pairs 
are placed at either termini of the 3BP2 linker in the Abl-SH3-3BP2 contiguous receptor 
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ligand biosensor, it should be possible to distinguish a fluorescence change between the 
intra and inter-molecular associations of Abl-SH3 and its ligand (Figure 3.1-2). As the 
association of Abl-SH3 with its ligand changes from intra to inter, the distance between 
the FRET pair will change, thus changing the efficiency of FRET exchange, and hence 
creating effective biosensor. This type of chemical labeling is analogous to the 
incorporation of different green fluorescent protein (GFP) derivatives at the termini of 
recombinant proteins, by standard D N A cloning methodologies (Tsien, 1998). 
+ LiqancL, 
- Ligand 
Figure 3.1-2. Design of Abl-SH3-3BP2 F R E T biosensor. A change in ligand binding 
results in a change in the efficiency of FRET transfer. 
Synthesis oftheAbl-SH3-3BP2 contiguous FRET biosensor 
There are four possible ways to ligate the Abl-SH3 domain to the 3BP2 sensor 
peptide: first, N-terminus to N-terminus; second, C-terminus to C-terminus; third, C-
terminus Abl-SH3 to N-terminus 3BP2 sensor peptide; and fourth, N-terminus Abl-SH3 
to C-terminus 3BP2 sensor peptide. Careful analysis of the crystal structure of the Abl-
SH3 domain and its 3BP2 ligand (Figure 3.1-3) suggested that the optimal topology for a 
contiguous receptor ligand construct would be to link the two constructs via a poly-
glycine linker using the first and third of the strategies listed above. 
To determine the optimal length for the linker a region, a series of constructs were 
designed where the number of glycines, which constitute the linker, were either 2, 10, 12, 
or 14. The construct where n=2 acted as the control, since the linker length is too short to 
permit an intramolecular association. All the constructs had the potential to interact in an 
intra- or inter-molecular fashion, the former leading to self association. Size exclusion 
chromatography was used to establish the oligomerization states of the constructs at two 
different concentrations, 1 ^ M and 0.25 -uM, and the data indicated that a linker region 
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containing 12 or 14 glycines is optimal for the desired intra-association between 3BP2 
and AM-SH3 (Cotton, unpublished). Thus, the synthesis strategy for the 3BP2 sensor 
peptide was as follows: H2N-Lys[Rh]-(Gly)n-(3BP2)-Ahx-Arg-Ala-Lys[Fl]-CONH2 (1), 
where [Rh] and [Fl] are the fluorophores tetramethylrhodamine and fluorescein, FRET 
acceptor and donor pair, (Gly)n is the flexible linker, Ahx is aminohexanoic acid, used as 
a spacer, and (3BP2) corresponds to the amino acid sequence PPAYPPPPVP. 
J3BP2 
NH2 ^ C 0 2 H 
Figure 3.1-3. Crystal structure of Abl-SH3 complexed with 3BP2 ligand. 
As was pointed out above, there are two efficient ways of ligating Abl-SH3 to the 
3BP2 sensor peptide, N-terminus AW-SH3 to N-terminus 3BP2 sensor peptide and C-
terminus Abl-SH3 to N-terminus 3BP2 sensor peptide. The first product was generated 
via a purely synthetic thioether ligation strategy, and the second ligation product was 
prepared using the protein semi-synthesis strategy EPL. 
Synthesis ofAM-SH3-3BP2 FRET Biosensor Using a Thioether Strategy 
The "amino group of a peptide or protein has a significantly lower pKa (6.8-7.9) 
than side-chain amine groups, thus it can be chemoselectively alkylated and acylated. 
Pioneering work done by Wetzel and co-workers showed that at pH 6.5 peptides can be 
iodoacetylated specifically at the N-terminus (Wetzel, 1990). The mechanism of a 
thioether ligation requires the presence of a nucleophilic thiol, which reacts with an 
electrophilic acetylated peptide (Figure 1-4). As illustrated in Figure 3.1-4A, the 
synthetic strategy called for the chemoselective thioether ligation between the N-
iodoacteylated 3BP2 sensor peptide of sequence IAc-(Gly)l 1-3BP2 and a synthetic Abl-
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S H 3 mutant, containing a unique cysteine residue at the N-terminus (Cys-Abl-SH3 (2)). 
Both the 3BP2 sensor peptide (1) and synthetic Cys Abl-SH3 (2) constructs were 
synthesized using the in situ neutralization/HBTU activation protocol for Boc SPPS 
(Schnolzer, 1992). The 3BP2 sensor peptide (1) was then idodactelyated in solution at the 
N-terminus using iodoacetic acid in tetra-hydrofuran (THF) at pH 6.3. The N-
iodoacetylated 3BP2 peptide (IAc-3BP2) (3) and the synthetic Cys-Abl-SH3 (2) products 
were purified and characterized before ligation. 
A. Thioether Synthesis Strategy B. Ligation reaction 
IAc 
HS-| 
N-Cys' 
CO-* 
SH3 
cp^i 
8M Urea 
0.1 M Phosphate 
Buffer pH = 7.5 
CO^ 
< * H r ^ S ^ SH3 
r ' 
COsH 
HPLC 
T = 0 min 
Cys-Abl-SH3 
IAC-3BP2 
J 
8M Urea 
0.1 M Phosphate 
Buffer pH = 7.5 
HPLC 
T = 60 min 
Cys-Abl-SH3 
IAC-3BP2 
L_-j~A-
ESMS 
Expected mass = 9370.5 Da g370 q + 1 3 Da 
L 
Figure 3.1-4. Synthesis a n d characterization of A b l - S H 3 - 3 B P 2 F R E T biosensor 
prepared by a thioether ligation approach (4). ( A ) Thioether synthesis strategy. (B) 
R P - H P L C and E S M S characterization of thioether Abl-SH3-3BP2 F R E T biosensor. In 
the H P L C traces of the crude ligation reaction (4) indicates the ligation product. T h e 
H P L C gradient at T = 0 m i n is 15-55%B, while that at T = 60minis 3 0 - 5 5 % B , both over 
30 min. E S M S characterization of the ligation product (4) by E S M S gave the correct 
mass [observed mass = 9370 ± 0.8; expected average mass = 9368]. 
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High concentrations of Cys-Abl-SH3 (2) and IAc-3BP2 (3) sensor peptide were 
ligated in 8 M urea, 0.1M phosphate buffer, p H 7.5 for 1 hour. T h e thioether ligation 
product w a s then purified by preparative H P L C and characterized by electrospray mass 
spectrometry ( E S M S ) . Figure 3.1-4B depicts the H P L C analysis of the ligation from 
time t = 0 minute to completion at t = 60 minutes, and E S M S characterization of the 
thioether ligation product. 
H2N -Cys-f INTEIN HJCB Bead. 
Recombinant Abl-SH3 
Synthetic 3BP2 FRET ligand 
A+thiols and 1 0 % DMSO 
'Lys N- rec. AUI-SH3 -CONH-Cys-Lys-(Glyn)- 3BP2 
Semi-Synthetic Receptor-Ligand construct 
E S M S 9370.0+ 0.5 Da 
Expected: 
9370.5 Da 
'- . 
9040 B200 9360 9520 m/7 flmu 
Figure 3.1-5. Synthesis and characterization of Abl-SH3-3BP2 F R E T biosensor 
prepared by EPL. (A) EPL synthesis strategy. (B) HPLC and E S M S characterization 
of EPL Abl-SH3-3BP2 FRET biosensor (7). Addition of 10% D M S O to EPL ligation 
reaction resulted in formation of the semi-synthetic receptor-ligand construct, whose 
mass was confirmed by ESMS. A linear gradient of 0-73% over 30 min was employed in 
the H P L C of the crude ligation reaction. 
Synthesis of AM-SH3-3BP2 FRET biosensor using EPL 
T h e protein semi-synthesis strategy Expressed Protein Ligation w a s used to ligate 
the C-terminus of Abl-SH3 to the N-terminus of the 3 B P 2 sensor peptide. A s depicted in 
Figure 3.1-5A, Abl-SH3 is expressed recombinantly as a See V M A - i n t e i n - C B D fusion 
protein (5). T h e fusion protein (5) is then reacted with an N-terminal cysteine version of 
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the 3BP2 sensor peptide, Cys-3BP2 (6), in the presence of thiophenol, to generate the 
semi-synthetic Abl-SH3-3BP2 FRET biosensor (7). This procedure is depicted by the 
mechanism of EPL shown in Figure 1-5C and was discussed above. 
Analysis of the two AM-SH3-3BP2 biosensor constructs 
Having successfully synthesized both Abl-SH3-3BP2 biosensor constructs, the 
next step was analyzing the structural and functional properties of the purified molecules. 
A series of circular diochroism (CD) spectroscopy experiments were conducted to 
determine if the ligation products were folded. The thioether ligation product had a C D 
characteristic of an AM-SH3-3BP2 receptor ligand complex (4) (Figure 3.1-6) (Viguera 
et al, 1994). In contrast, the C D of the EPL product could not be determined, due to the 
insoluble nature of the construct. While it is not clear why the EPL construct behaved 
differently from the thioether construct, one possibility is that the manner in which the 
ligation was performed, C-terminus of Abl-SH3 to N-terminus of 3BP2 ligand, affects the 
folding of the protein. 
5000 
-5000-
-10000-
-15000 
wtAbl-3BP2 
Thioether Construct 
Figure 3.1-6. Far uv Circular Dichroism (CD) analysis of AM-SH3-3BP2 thioether 
construct. The spectra of Abl-SH3-3BP2 thioether construct (4) as compared to wtAbl-
SH3-3BP2: the fold of the thioether construct is similar to that of wildtype. 
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Encouraged by the C D analysis of the thioether ligation product, a decision was 
made to proceed with fluorescence spectroscopy analysis. The goal was to monitor the 
change in FRET between Fl and Rh as the intramolecular association between 3BP2 and 
Abl-SH3 is displaced by an exogenous competing ligand. To monitor FRET, the 
thioether construct was excited at 490nm (Fl absorption), and fluorescence emission was 
monitored at 520nm (Fl emission) and 580nm (Rh emission). In the absence of the 
competing ligand, FRET was observed between Fl and Rh. This is evidenced by the 
intense emission at 580nm compared to that at 520nm in Figure 3.1-7A. 
control [NS] 
p40 ligand 
[peptide] (iM 
Figure 3.1-7. Analysis of AM-SH3-3BP2 thioether construct. (A) Fluorescence 
spectrum of AM-SH3-3BP2 thioether construct (4). Sample was excited at 490 nm (Fl 
absorption) and fluorescence emission is monitored from 500-600 n m (Fl and Rh 
emission, respectively). FRET exchange occurs between the FL and Rh fluorophores as 
evidenced by the intense emission at 580nm compared to that at 520nm. (B) FRET 
analysis of thioether ligation product. Plot of the concentration of competing ligands, 
P40 (12) and N S (13), versus 580:520 nm fluorescence intensity. There is an increase in 
FRET when P40 (12) ligand is used, but no change is observed when the non-specific 
ligand (NS (13)) is used. 
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The next step was to titrate a competing ligand into the thioether Abl-SH3-3BP2 
biosensor construct (4). The titration study was conducted on a small scale, using a non-
specific ligand (NS (13)) (amino acid sequence, Y S P W T N F ) that has no affinity for Abl-
SH3, and a ligand P40 (12) (amino acid sequence, APTYSPPPPP ) that is known to bind 
Abl-SH3 with a Kd of 7.0p-M. Initial experiments were encouraging in that a dose 
dependent increase in the 580:520nm FRET ratio was observed using P40 (12) as the 
competing ligand, but no significant change was observed with N S (13) (Figure 3.1-7B). 
This result is consistent with the original biosensor design. Unfortunately, attempts to 
reproduce these data were largely unsuccessful, in most cases both the N S (13) and P40 
(12) ligands yielded the same titration results (data not shown). It is certainly 
conceivable that the variation in the results was linked to differences in the Abl-SH3-
3BP2 biosensor preparations (several batches were used in the course of these studies). 
However, at this stage it cannot be ruled out that the original design of the contiguous 
receptor-ligand construct was in some way flawed. Most notably, by covalently linking 
the 3BP2 ligand to its SH3 receptor we may have increased the affinity of the ligand for 
the receptor, making a tighter association of the two, and thus harder to illicit a change 
when the competing P40 ligand is introduced. 
Although a biosensor for AM-SH3 was never realized, Abl-SH3 did prove 
significant to the development of expressed protein ligation. As reported in a paper 
published in 1999, Abl-SH3 was used extensively to investigate the scope and limitations 
of EPL (Ayers et al, 1999). Specifically, Abl-SH3 was used to investigate the effects of 
chaotropic agents on EPL. 
Effect of chaotropic agents on E P L 
An important feature of all chemical ligation approaches is that they can be 
performed in the presence of organic solvents or chaotropic agents such as guanidine 
hydrochloride (GdmCl) or urea (Muir et al, 1994) (Muir et al, 1997). This frequently 
turns out to be of great practical value since many polypeptide reactants are insoluble in 
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aqueous buffers at neutral pH, particularly at the millimolar concentrations required for 
efficient ligation. Since the same solubility problems may be encountered in certain 
EPL-based syntheses (as was the case with the EPL ligation of Abl-SH3 fusion protein 
(5) and Cys-3BP2 (6) sensor peptide), it was decided to explore how tolerant the 
approach was to increasing amounts of GdmCl in the reaction buffer. 
The model ligation reaction between Abl-SH3 fusion protein (5) and the synthetic 
peptide NH2-Cys-Gly-Arg-Gly-Arg-Gly-Arg-Lys[Fl]-CONH2 (8) was carried out in the 
presence of 0, 2, 3, 4, and 5.5M GdmCl at pH 7.0. The sequence of peptide (8) was 
designed to be highly soluble at neutral pH, and the fluorescent probe was incorporated to 
provide a convenient way of monitoring the ligation reactions by RP-HPLC using 490nm 
detection. 
As summarized in Figure 3.1-8A, essentially no difference was observed in the 
yield of the ligation product of reactants (5) and (7), namely, Abl-SH3-Cys-Gly-Arg-Gly-
Arg-Gly-Arg-Lys[Fl]-CONH2 (9), on going from 0 to 2 M GdmCl. However, a dramatic 
reduction in yield was observed on going from 2 to 3 M denaturant. Since native 
chemical ligation reactions are unaffected by the presence of 6 M GdmCl (Muir et al, 
1997), this result implies that the initial "thioester derivative of Abl-SH3 is not formed at 
GdmCl concentrations above 2M. This presumably translates to structural perturbation 
of the -See-VMA intein at higher GdmCl concentrations. Although extremely high 
concentrations of chaotrope are not tolerated, the observation that EPL can be performed 
in 2 M GdmCl is likely to be of considerable utility, and complements the use of 1 0 % 
D M S O as a solubilizing agent for EPL. 
The utility of 2 M GdmCl was illustrated by the ligation of a synthetic 34-mer 
peptide derived from the C-terminal region of the Esherichia Coli o specificity factor, 
N H 2 - C N T D Y L E E V G K Q F D V T R E R I R Q I E A K A L R K L R H - C O N H 2 (10), to Abl-SH3 
fusion protein (5) using EPL. Peptide (10) has poor solubility (low u M ) in aqueous 
buffers at neutral pH, but can be solubilized at millimolar concentrations in the presence 
of 2 M GdmCl. Attempts to ligate (10) to (5) in the absence of GdmCl led to no 
detectable product formation (data not shown), whereas (5) was clearly converted to the 
desired semi-synthetic protein Abl-SH3-CNTDYLEEVGKQFDVTRERIRQIEAKALRK 
LRH-CONH2 (11) when 2 M GdmCl was included in the ligation buffer (Figure 3.1-8B). 
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This result reflects the known relationship between high reactant concentrations and 
chemical ligation efficiency (Muir et al, 1997). 
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Figure 3.1-8. Effect of guanidine hydrochloride on EPL. (A) Ligation of Abl-SH3-
intein fusion protein (5) to synthetic peptide (8) in the presence of increasing 
concentrations of GdmCl. The yield of each reaction is represented as a percentage of the 
total product formed in O M GdmCl, and was determined by integration of the product 
peak in the corresponding HPLC chromatogram. (B) HPLC analysis of crude ligation 
mixture obtained from reaction with fusion protein (5) and a70 region 4.2 (10) in the 
presence of 2 M GdmCl. A linear gradient of 0-73% buffer B over 30min was employed. 
The ligation product elutes as a single peak at 23.60 minutes. The diamond indicates an 
unidentified nonpeptidic impurity. 
Concluding remarks on the Abl-SH3-3BP2 biosensor - significance to E P L 
development 
In the words of Bruce Merrifield when describing his attempt to synthesize the 
composite hormones angiotensinylbradykinin and bradykininylbradykinin, "the syntheses 
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were successful and chemically interesting, but the biological results were not as hoped 
for" (Merrifield, 1993). The same can be said for the synthesis of the thioether and EPL 
based versions of an Abl-SH3-3BP2 biosensor. Although a contiguous receptor ligand 
biosensor for the Abl-SH3-3BP2 construct was not realized, the scope and limitations of 
EPL were explored through a series of model studies. Specifically, a paradigm was 
developed for site-specifically incorporating fluorophores into proteins using expressed 
protein ligation. This procedure was used to site-specifically incorporate a fluorescein 
and rhodamine fluorophore into the proline rich 3BP2 ligand of Abl-SH3. The utility of 
this procedure is readily applicable to the labeling of other protein constructs (see Section 
3.3.). 
In addition, the model investigations of Abl-SH3 have revealed that EPL can be 
performed in the presence of moderate concentrations of the chemical denaturant GdmCl 
and the organic solvent D M S O . This finding has important implications when using 
poorly soluble synthetic peptide reactants, as illustrated by the synthesis of the semi-
synthetic protein products outlined above. 
Finally, the properties of EPL outlined in this application will be used repeatedly 
in subsequent applications in this thesis, and continue to be used routinely in the Muir 
lab. 
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3.2 Site -Specific Incorporation of Post-Translational Modifications 
into Type I Transforming Growth Factor p Receptor 
Part of this work conducted in collaboration with Morgan Huse 
Introduction to T G F p Type I receptor - Significance to E P L development 
The synthesis of many proteins is not complete when the protein is released from 
the ribosome. A large number of proteins are modified after translation and these 
modifications play an important role in the function of the protein. Post-translational 
modifications are central to the molecular events controlling cellular signaling networks 
(Lee, 2001; Massague, 2000; Nalivaeva, 2001) and are, in effect, nature's method for 
conferring functional diversity onto the same translated sequence. It has been difficult, 
using standard recombinant D N A technology, to produce homogeneous samples of 
proteins that have defined and specific patterns of post-translational modifications. This 
inability has hindered biochemical and structural investigations into the role these 
modifications play in regulating structure and function. Protein chemical ligation could 
have a major impact in this area. An example of this is the regulation of the transforming 
growth factor P (TGFP) receptor family through serine/threonine phosphorylation near 
the amino terminus of the cytoplasmic kinase domain (Massague, 1998). 
The TGFP signaling pathway plays a prominent role in a variety of cellular 
functions including modulation of cell growth, extra-cellular matrix production, and cell 
death via apoptosis (Massague, 1998). The protein growth factor, TGFp transduces 
signals via a receptor complex composed of two transmembrane serine-threonine kinases, 
the TGFP receptors I and II (T^R-I and T0R-II). Oligomerization of the two receptors 
induced by TGFP binding causes ipR-II to hyperphosphorylate T0R-I within a highly 
conserved N-terminal regulatory region called the GS region, named for the highly 
conserved 185TTSGSGSG192 sequence contained within it. Activated T|3R-I then 
phosphorylates members of the Smad family of transcription factors, which carry the 
signal to the nucleus (Figure 3.2-1). 
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Figure 3.2-1. T G F p signaling pathway. 
Phosphorylation of four to five of the serines and threonines within the 
185TTSGSGSG192 sequence is thought to be required for full activation of T(3R-I signaling 
(Wieser, 1995). However, the level to which hyperphosphorylation activates the kinase 
towards its natural substrate remains unknown, and the molecular mechanism of how this 
post-translational event leads to kinase activation has yet to be resolved. The crystal 
structure of the cytoplasmic domain of T|3R-I (Figure 3.2-2A) (Huse, 1999) showed that, 
in its unphosphorylated state, the G S region adopts an inhibitory conformation that 
maintains the protein kinase domain in a catalytically inactive conformation. Thus, 
phosphorylation within the GS region would presumably activate the kinase by disrupting 
inhibitory interactions (a de-repression model for kinase activation) (Figure 3.2-2B). 
Mutagenesis data, however, suggest that the situation may be more complex (Wieser, 
1995; Willis, 1996). The phosphorylated GS region may also activate the receptor in a 
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Figure 3.2-2. T p R - 1 d o m a i n organization and activation model. (A) Overall domain 
architecture for T|3R-1. R e d denotes the G S region of T|3R-1 and gray the Ser/Thr kinase 
domain. T h e crystal structure of the unphosphorylated cytoplasmic Ser/Thr kinase 
domain is s h o w n adjacent to a schematic representation of it. In both the crystal structure 
and the schematic representation the G S region (in red) and activation segments (in 
green) are identified. (B) Model for TpR-1 activation. In this model 
hyperphoshorylation derepresses the kinase and creates a docking site for the R-SMAD 
substrate, which gets phosphorylated by T|3R-I. 
positive way, perhaps by adopting a new structure that complements kinase activity, or 
by recruiting substrate. 
To fully understand the molecular mechanisms underlying signal transduction 
processes such as T|3R-I activation, it is necessary to have access to chemically defined 
phospho-proteins for biochemical and biophysical analysis. This requirement is usually 
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unattainable using simple genetics due to the inability to encode for a phospho-amino 
acid using standard protein expression technologies. Several attempts to produce 
homogeneously phosphorylated samples of T^R-I by either coexpression with T|3R-II, or 
in vitro phosphorylation were unsuccessful (M. Huse, personal communication). The 
field of protein semi-synthesis offers a solution to this problem in that it allows for the 
incorporation of a suitably modified synthetic cassette (which would presumably be 
homogeneous) into the protein. It was decided to exploit the protein semi-synthesis 
strategy EPL, to join a synthetic phospho-peptide segment to a recombinant T^R-I target 
protein, ATPR-I, producing a full-length homogeneously phosphorylated T|3R-I receptor, 
residues 175-503 (Figure 3.2-3). 
Expressed protein 
His-tag-IEGR-
/ 
Xa 
GSATpR-l 
Synthesized peptide 
GS-OBio or GS-4 
Chemical ligation 
Phosphorylation 
Sites 
Active Site 
Final product 
GS-OBioTpR-l or GS-4T0R-I 
Figure 3.2-3. Protein semi-synthesis of TpR-I. The TpR-I cytoplasmic domain 
(GSATpR-I (16)), shown in gray ribbon, was expressed in SF9 cells downstream of a 
polyhistidine tag, which was later removed by proteolytic cleavage with Factor Xa. 
GSAT^R-I (16) is then ligated to the synthetic G S peptide (GS-OBio (14) or GS-4 (15)). 
The synthetic peptide is shown in red with the residues phosphorylated in this study 
depicted as blue spheres in the model. Following ligation the final product (GS-
OBioTpR-I (17) or GS-4TPR-I (18)) is obtained. 
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In section 3.1, expressed protein ligation was defined as a protein semi-synthesis 
method for ligating synthetic fragments to the C-terminus of recombinant proteins. In the 
case of TpR-I, the G S region is located near the N-terminus of the kinase domain. Thus, 
in this case EPL must be used to ligate a synthetic peptide to the N-terminus of the 
recombinant fragment. Accordingly, this synthetic peptide must contain multi-
phosphorylated amino acids with a C-terminal thioester. This work required the 
development of new chemistry, and signified a broadening of the scope of EPL to include 
the ligation of synthetic fragments to the N-terminus, as well as the C-terminus, of 
recombinant proteins (Huse, 2000). 
Design and Synthesis of hyperphosphorylated TpR-I 
Currently there are two strategies for the synthesis of phosphopeptides; the SPPS 
approach using protected phosphoamino acids (Perich, 1991; Perich, 1988), and the 
global phosphorylation approach, which involves post synthetic phosphorylation of 
unprotected hydroxyl groups following the chain-assembly (Larsson, 1994; Perich, 
1988). Due to the instability of phospho-amino acids during the final HF treatment in 
tert-butoxycarbonyl (Boc) SPPS, a 9-fluorenylmethoxycarbonyl (Fmoc) SPPS approach 
must be used for synthesis of these peptides. Unfortunately, the Fmoc approach has been 
incompatible with the generation of "thioesters. This is because treatment of the resin 
bound peptide with piperidine during Fmoc deprotection at each cycle of peptide 
synthesis results in aminolysis of the thioester during the chain assembly. However, 
several advances have been made recently that to varying degrees address this problem. 
These include the use of modified Fmoc deprotection conditions (Li, 1998), the use of 
Lewis-acid mediated thiolysis conditions (Sewing, 2001; Swinnen, 2000) and the use of 
specialized resin-linkers such as the backbone-amide linker (Alsina, 1999) and the 
sulfonamide safety-catch linker (Ingenito. R., 1999; Quaderer, 2001; Shin, 1999). The 
last of these is of particular relevance to the generation of phosphopeptide "thioesters. 
The sulfonamide safety-catch linker system was first described in the early 
1970's by Kenner and co-workers (Kenner, 1971) and was recently refined by Ellman 
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and colleagues (Backes, 1996; Backes, 1999). In the safety-catch approach, the peptide is 
synthesized on the sulfonamide-resin using standard Fmoc SPPS protocols. Then, prior 
to cleavage of the peptide from the resin support, the sulfonamide linker is activated with 
a haloacetonitrile to form an extremely reactive N-cyanomethylacylsulfonamide, which 
when further reacted with a nucleophilic species such as a thiol, releases the peptide as a 
"thioester. The aim of this thesis section was to explore the safety-catch linker as a viable 
method for the generation of phospho-thioester peptides, and to determine if its use in 
conjunction with E P L could allow for the site-specific phosphorylation of proteins like 
TpR-I. 
T w o semi-synthetic T^R-I targets were selected: first, a T|3R-I with an 
unphosphorylated G S region, to be used as control, and second, a T^R-I species in which 
Thr185, Ser187, Ser189, and Ser191 of the G S region were phosphorylated. For both TpR-I 
targets, the G S region, residues 175-195, were synthesized as a peptide "thioester (Figure 
3.2-4), which was then joined to the remainder of the recombinantly expressed TpR-I 
cytoplasmic domain (GSAT^R-I (16)) by E P L under physiological conditions. 
B. Fmoc SPPS A. Boc SPPS 
H,-(MBHA) 
Trltyl-p-mercapto propionic add 
4- Sultamylbutyryl Am resin 
I.) Couple first amino add X 
MBHA) 
I.) Deproted trityl group 
Ii.) Couple first amino add 
ih-(ME3HA) 
Boc—fGS-4 peptide 
M B H A ) 
ill.) SPPS 
iv.) HF cleavage 
n h H G.S-0 peptide 
GS4-BIO 
BtoWn^mWJUYpOMTTSGSGSGLPL-OSR 
17S 1« 
Boc —{gs-4 peptide 
lv.) Cleave with thiols (RSH) 
v.) Deprotect with TFA and scavengers 
Boc-| SS-4 peptide f—hi 
TTLKDUYDl/lfpTTpilCip'JGp'jGLPLOSBll 
175 195 
Figure 3.2-4. G S thioester peptide synthesis strategies. (A) Boc SPPS of non-
phosphorylated G S thioester peptide (GS-OBio (14)). ( B ) F m o c SPPS of tetra-
phosphorylated G S thioester peptide (GS-4 (15)). 
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Synthesis of the unphosphorylated G S thioester peptide 
The unphosphorylated GS thioester peptide (GS-OBio (14)) was prepared by Boc 
SPPS. The "thioester moiety was introduced using trityl P-mercaptopropionic acid as a 
handle on an MHBA resin (Camarero et al, 1998) (Figure 3.2-4A). A biotin molecule 
and glycine spacer were included at the N-terminus of GS-OBio (14) to facilitate 
purification of the ligation product from unreacted GSATpR-I (16). The peptide was 
purified by semi-preparative reverse phase HPLC and characterized as GS-OBio by 
analytical HPLC and ESMS (Figure 3.2-5A). 
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Figure 3.2-5. Characterization of G S peptides. (A) Analytical RP-HPLC (1) and 
E S M S (2) of crude GS-0Bio(14) peptide. RP-HPLC gradient is 30-50% B over 30 min. 
[Observed mass= 2542.0 ± 0.1 Da; expected (average isotopic mass) = 2540.7 Da.]. (B) 
Analytical RP-HPLC (1) and E S M S (2) of purified GS-4 (15) peptide. RP-HPLC 
gradient is 30-50% B over 30 min. [ Observed mass = 2597.0 + 0.5 Da; expected 
(average isotopic mass) = 2596.5 Da]. 
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Synthesis of the tetra-phosphorylated G S thioester peptide 
The tetra-phosphorylated G S thioester peptide (GS-4 (15)) was made via Fmoc 
SPPS on the sulfonamide based safety-catch resin, 4-Sulfamylbutyryl A m resin (Figure 
3.2-5B). The close apposition of protected phosphate groups during the GS-4 (15) 
synthesis could lead to slow acylation kinetics during this part of the chain assembly. 
Accordingly, residues from Met184 through pSer191 were double coupled with extended 
reaction times, and benzotriazole-1-yl-oxy-tris-pyrrolidino-phosphonium 
hexafluorophosphate (PyBOP) was used as the activation agent in all phospho-amino 
acid couplings. Elongation of the peptide continued until Met184, at which point the 
synthesis was suspended in order to analyze the quality of the peptide after the addition 
of the four phosphorylated amino acids. 
Following activation with iodoacetonitrile (ICH2CN), a series of trial cleavage 
reactions were conducted in order to find the optimal conditions for cleaving the peptide 
from the sulfonamide resin. Specifically, the use of propylamine, ethanethiol and 
benzylmercaptan, in combination with various bases and organic solvents was 
investigated. Treatment with benzylmercaptan yielded the best results and thus was used 
to cleave a portion of the protected peptide from the sulfonamide resin. The cleaved 
peptide was then deprotected, under optimized conditions, using 95%TFA/p-cresol/H20 
for 3 hours. Analysis of the crude product indicated the expected mass of the tetra-
phosphorylated peptide (Figure 3.2-5B). It is worth noting that obtaining a mass of the 
peptide was not an easy task. Due to the overall negative charge of the peptide, it did not 
"fly" well (i.e., it did not ionize well) in the standard ESMS. After considerable effort, 
the mass of the peptide was determined using a Triple Stage Quadrupole (TSQ) mass 
spectrometer, courtesy of Julio Caesar Padavon and Brian Chait. 
Confident about the correct synthesis of the first half of the peptide, the synthesis 
was completed using standard Fmoc SPPS procedures. The N-terminal Thr175 was 
incorporated as an N" Boc derivative to prevent its amino functionality from attacking the 
sulfonamide linker during cleavage. (Note, like GS-OBio (14), GS-4 (15) was initially 
biotinylated at the N-terminus. Cleavage revealed a contaminating degradation product 
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144 Da less than the expected mass. Peptide mapping studies localized the modification 
to the N-terminus of the peptide. The contaminant did not bind avidin beads, and it was 
concluded that the biotin had fragmented at some point during the activation/cleavage 
process.) Full length GS-4 (15) peptide, as illustrated in figure 3.2-4B, was cleaved from 
the sulfonamide resin in a manner similar to that described for the truncated Met184 
peptide above, and analyzed by reverse phase HPLC and TSQ-MS. 
Similar to the truncated Met184 peptide, mass spectrometric analysis of the GS-4 
(15) was not easy, again presumably because of the four phosphate groups. As a result, 
GS-4 (15) was ligated to a carrier protein in order to aid the mass analysis. The synthetic 
Cys-Abl-SH3 (2) construct made in Section 3.1 was used for this purpose. Ligation was 
preformed using the standard EPL buffer (0.2M sodium phosphate, 0.2M NaCl, pH 7.2) 
and allowed to proceed overnight. Analysis by E S M S yielded the expected mass of the 
ligated product (data not shown), which indicated the successful synthesized the GS 
region of TpR-I, with four site-specific phosphorylation site. 
Ligation of GS-OBio and GS-4 to GSATBR-I 
TpR-I minus the G S region (GSATpR-I (16)), residues 196-503, with Leu196 
mutated to Cys to enable ligation, was expressed in SF9 cells downstream of a 
polyhistidine tag (Figure 3.2-3). The ligation site was chosen on the basis of analysis of 
the crystal structure of unphosphorylation T0R-I as well as inspection of the sequence 
conservation in that portion of the G S region. Following Ni2+ affinity purification, the 
affinity tag was cleaved with the protease Factor Xa to expose Cys196, and further 
purified using y-phosphate conjugated A T P sepharose. Ligation reactions were 
performed in the presence of 5 0 m M mercaptoethanesulfonic acid (MESNA) as the thiol 
cofactor. GSATpR-I (16) displayed a tendency to aggregate, so ligations were carried out 
at low protein concentration (0.05-0. I m M ) and at low temperature (4° C) in order to slow 
down this aggregation. Do note that denaturants could not used in this system, as their 
addition led to an irreversible loss in TpR-I kinase activity. Peptide concentrations were 
kept high, between 0.5 and ImM, to generate pseudo-first-order reaction kinetics. 
Unreacted peptide was recovered by gel filtration and could be recycled for multiple 
ligations. The GS-OBio (14) ligation reaction was efficient, proceeding to - 7 0 % 
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completion after 10 hours, as judged by denaturing polyacrylamide gel electrophoresis. 
The GS-4 ligation was significantly slower, only 6 0 % complete after 24 hours. 
After gel filtration, the unphosphorylated TpR-I ligation product (GS-OBioTpR-I 
(17)) was separated from unreacted GSATpR-I (16) using monomeric avidin agarose. 
The purified GS-OBioTpR-I (17) product was analyzed by analytical H P L C and E S M S 
(Figure 3.2-6A). The tetra-phosphorylated TPR-I ligation product (GS-4TPR-I (18)) was 
purified from GSATpR-I (16) by anion exchange chromatography. Purified GS-4T0R-I 
(18) product was analyzed by analytical H P L C and M A L D I M S (Figure 3.2-6B). Using 
these ligation and purification conditions, GS-OBioTpR-I (17) and GS-4TPR-I (18) could 
be routinely isolated in 10-20% overall yield. These amounts are sufficient for detailed 
biochemical and biophysical studies. 
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Figure 3.2-6. Characterization of TpR-I constructs. (A) Analytical RP-HPLC (1) and 
E S M S (2) of pure GS-OBioTbR-I (17). RP-HPLC gradient is 0-100% B over 30min. 
[Observed mass = 37,698 ± 7.2 Da; expected mass (average isotopic mass) = 37,695.2 
Da]. (B) Analytical RP-HPLC (1) and MALDI-TOF M S (2) of pure GS-4TbR-I (18). 
RP-HPLC gradient is 0-100% B over 30min. [Observed mass = 37731 ± 18 Da; 
expected mass (average isotopic mass) = 37731.9 Da]. 
Biochemical analysis of the unphosphorylated and tetra-phosphorylated 
TpR-I constructs 
To characterize the extent of TpR-I activation induced by hyperposhporylation, an in 
vitro kinase assay was performed, comparing GS-4T0R-I (18) and GS-0BioTpR-I (17) 
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with each other and against GSATpR-I (16). A slightly larger recombinant fragment of 
TPR-I, encompassing both the G S region and the kinase domain (termed T^R-Icyt and 
used in previous crystallographic analysis (Huse, 1999)), was also included for 
comparison. A C-terminal fragment of Smad2 was used as a substrate in this assay. This 
region, termed the M H 2 domain, comprises residues 241-467 of Smad2 and contains both 
known phosphorylation sites, Ser465 and Ser467, in the protein. Thus, this domain can be 
considered a physiological protein substrate for T(3R-I. In a typical kinase reaction, 
lOpmol of T^R-I were mixed with 80pmol of Smad substrate in 15mL of kinase buffer 
containing trace amounts of [y-32P]ATP. Samples were subjected to gel electrophoresis 
and visualized by autoradiography. 
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Figure 3.2-7. Phosphorylation of the Smad2 M H 2 domain by TpR-I constructs. 
Smad2 phosphorylation in three independent kinase assays have been combined and 
quantified. GS4TPR-I (18) displays more than a 40-fold increase in kinase activity 
relative to both GS-OBioTpR-I (17) and GSATpR-I (16). 
Under the conditions of this experiment, GS-4TpR-I (18) displayed more than a 
40-fold increase in kinase activity relative to both GS-0BioT(3R-I (17) and GSAT(3R-I 
(16) (Figure 3.2-7). GS-OBioTbR-I (17) did not demonstrate comparable activation 
relative to TpR-Icyt and GSATpR-I (16), indicating that the increase observed for GS-
4T(3R-I (18) is dependent upon phosphorylation, and not a result of the ligation chemistry 
or the Leu to Cys mutation. Furthermore, the observed increase in GS-4T(3R-I (18) 
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kinase activity relative to GSATpR-I (16) indicated that the phosphorylated G S region 
does indeed play an active role in the upregulated state of the kinase, and argues against a 
simple de-repression model. In this assay, a 3-fold difference in activity is observed 
between TpR-Icyt and both GSATpR-I (16) and GS-OBioTpR-I (17). This difference 
could not be explained during this study, but we do note that it does not affect our 
conclusions with regard to GS-4TPR-I (18), which is still activated by a factor of 10 
relative to TpR-Icyt. 
Concluding remarks on the semi-synthesis of TpR-I - significance to E P L 
development 
EPL has been effectively employed to produce homogeneous chemically defined 
samples of hyperphosphorylated T{3R-I. Access to these molecules allowed the level to 
which hyperphosphorylation activates the kinase to be quantified for the first time and, in 
addition, has provided evidence that the phosphorylated GS region may also activate the 
receptor in a positive way. This work also represents the first example in which a peptide 
has been ligated to a protein expressed in eukaryotic cells. In subsequent studies 
performed by Morgan Huse, access to a homogeneous preparation of 
hyperphosphorylated TpR-I allowed the molecular mechanism of receptor activation to 
be studied for the first time. Accordingly, phosphorylation was shown to increase the 
binding affinity of TpR-I for its natural substrate, the Smad2 transcription factor, and 
decrease the affinity for the inhibitory protein FKBP 12. These observations led to a new 
model of receptor activation in which phosphorylation of the receptor switches the 
protein from an inhibited state into an activated form capable of binding substrate. 
A n Achilles' heel of native chemical ligation and thus EPL, that has arguably 
restricted their application, is the technical difficulty associated with the preparation of 
synthetic peptide "thioesters. Here it was demonstrated, with the successful synthesis of 
the tetraphosphorylated GS-4 (15) peptide on the alkanesulfonamide "safety catch" resin, 
an effective method to combat this problem. With the synthesis of the tetra-
phosphorylated TPR-I receptor, it was also demonstrated that the alkanesulfonamide 
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resin, when used in conjunction with EPL, is a practical route to site-specifically 
incorporate multiple post-translational modifications into proteins. Previously, EPL had 
been used to attach a phospho-peptide to the C-terminus of a protein (Muir et al, 1998). 
Here it is demonstrated that phospho-peptides can be linked to the N-terminus and, by 
extension, incorporated into the middle of a protein via a sequential ligation strategy 
(Cotton et al, 1999). This EPL strategy may be readily adapted to study post-
translational modifications in other systems. 
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3.3 Site-Specific Incorporation of UV-Photo Cross-Linkers and 
Fluorescent Probes into E. Coli Sigma Factor a70 
Part of this work conducted in collaboration with Leonid Minakhin and Julio Camarero. 
Introduction to prokaryotic transcription-significance to E P L development 
In all organisms the enzyme RNA polymerase (RNAP) catalyzes the transcription 
of D N A into RNA. In prokaryotes, R N A P is made up of five subunits (a2, p, P', co) that 
together define the core RNAP. On its own, core R N A P cannot initiate transcription, as 
it cannot specifically bind promoter D N A to begin the synthesis of RNA. For promoter 
binding, core R N A P requires another subunit termed a sigma specificity factor (a). 
When the sigma factor binds to core R N A P it converts the core complex into what is 
known as the holoenzyme (0:2, P, P\ to and a), and it is this assembly that is able to 
initiate transcription (Burgess, 1969; Burgess, 1970). In Escherichia coli the primary 
sigma factor, sigma 70 (a70), directs transcription of housekeeping genes. It is 70 kDa in 
mass and is comprised of 613 amino acids, a70 has four conserved regions, each of which 
maps to a particular function in the transcription initiation process (Lonetto, 1992; 
Severinova, 1996) (Figure 3.3-1). In principle each stage of the transcription process can 
be regulated, but most regulation occurs at transcription initiation. In the case of sigma 
factors, regulation can occur either intra-molecularly, through auto-inhibition with a70 
region 1.1, or inter-molecularly, through interactions of a70 with regulatory proteins like 
bacteriophage AsiA. 
The bacteriophage T4 antisigma AsiA protein has been shown to inhibit E. coli 
a70 dependent transcription by binding to region 4.2 of a70 (Severinov and Muir, 1998) 
and interfering with its recognition of the -35 promoter element (Co I land, 1998; 
Severinova, 1998). AsiA is a 10 kDa protein expressed in the early stage of 
bacteriophage infection of E. coli (Orsini, 1993). It binds to a70 and efficiently inhibits 
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Figure 3.3-1. Domain organization of a70. The four conserved regions of a70 (regions 
1, 2, 3, 4) and their biochemical functions. 
transcription from early phage and most E. coli a70-dependent promoters (Figure 3.3-2). 
At the same time AsiA collaborates with MotA, the product of another early gene, to 
activate E. coli a70-dependent transcription of viral middle genes (Ouhammouch, 1994). 
At later stages of infection, the viral a-like protein gp55, a product of a middle gene, 
replaces the host a70-AsiA complex and directs R N A P core to late promoters of the T4 
phage (Kolesky, 1999). Thus, AsiA abolishes transcription from most host and early T4 
promoters and coactivates transcription of middle viral promoters (Colland, 1998; 
Severinova, 1998). 
Available data do not address whether the inhibitory effect of AsiA is direct (i.e. 
AsiA interacts directly with amino acids in a70 region 4.2 that would normally interact 
with bases of the -35 element), or indirect (i.e. AsiA interacts outside the DNA-binding 
surface of a region 4.2 and through a conformational change prevents E. coli a70 binding 
to -10/-35 promoters). In the absence of core R N A P , a70region 1.1 is believed to bind 
directly to a70region 4.2, preventing region4.2 from binding to the -35 promoter 
element, and thus inhibiting a initiation of transcription (Dombroski, 1992) (Dombroski, 
1993). Recent work in the Muir lab used a combination of heteronuclear N M R spectro-
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Figure 3.3-2. Bacteriophage T4 antisigma (AsiA) inhibition of a70 dependent 
transcription. AsiA, which is expressed during early stage of bacteriophage infection of 
E. coli, binds to o 70 and inhibits a 70 dependent transcription. While inhibiting a 70 
transcription, AsiA (with the aid of co-activators) also facilitates the transcription of 
alternative sigmas in middle transcription. 
scopy and segmental labeling techniques to study the putative interaction between 
regions 1.1 and 4.2 of a a70-like subunit from T. maritima o^ (Camarero, 2002). Initial 
results of this study do not support the idea of a direct interaction of regions 1.1 and 4.2, 
but do suggest that region 1.1 can block the binding of region 4.2 to specific targets like 
the -35 promoter D N A sequence or bacteriophage AsiA. Specifically, addition of AsiA 
to truncated cr^  lacking region 1.1 resulted in dramatic chemical shift perturbations within 
labeled region 4.2. No such changes were observed when the same amount of AsiA was 
added to full-length cr\ W e were interested in exploring whether the inhibitory effect of 
region 1.1 also occurs in a70, the natural binding partner of AsiA. Also, we wanted to 
quantify the putative effect of region 1.1 on the a70-AsiA interaction. 
Characterization of a70 inhibition at a molecular level is a prerequisite for fully 
understanding the mechanism and regulation of E.coli transcription initiation. The site-
specific incorporation of biophysical and biochemical probes into a70 would aid the study 
of these complicated interactions. Using chemistry-driven approaches, such as expressed 
protein ligation, to site-specifically incorporate biophysical and biochemical probes into 
a70, it has been possibly to map the a70-AsiA interaction, determine that AsiA inhibition 
of a70 is indirect, and provide the constructs for investigating whether region 1.1 
influences the dissociation constant (Kd) of the a70-AsiA interaction. 
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AsiA inhibition of a70 dependent transcription was addressed using a combination 
of genetic, biochemical, synthetic and combinatorial approaches. This has allowed us to 
extensively map the molecular interface between a70 and AsiA. The results indicate that 
T4 AsiA inhibits E. coli a70 transcription in an indirect manner, binding to amino acids in 
o™ region 4.2 that are not involved in recognition of the -35 promoter (Minakhin, 2001). 
The a70 region 4.2-AsiA interface is extensive, with multiple amino acids of region 4.2 
contributing to the interaction. In AsiA, however, the interaction site appears to be 
limited to the first 20 amino acids. 
To examine if region 1.1 influences the Kd of the a70-AsiA interaction, EPL was 
used to site-specifically label several versions of a70 with fluorophores for use in a 
fluorescence binding assay. The K<i of the a70-AsiA interaction cannot be determined by 
N M R experiments due to the sensitivity limits of the technique. For these reasons a 
fluorescence-based approach was sought. The constructs for the assay have been 
successfully synthesized and fully characterized, but, given the unanticipated difficulties 
in their synthesis (outlined below), they have not yet been applied in a fluorescence 
assay. However, the application of EPL to the semi-synthesis of a70 demonstrated, once 
again, the way in which probes can be site-specifically incorporated into proteins using 
this method. Also, due to the insoluble nature of region 4.2, several chaotropic and 
organic solvents, other than and including GdmCl and D M S O , were used during EPL 
ligation reactions, serving as a model system to further outline the scope of this 
technique. 
Mapping the molecular interface between cr70 and AsiA 
As mentioned above, a tour de force of scientific techniques ranging from purely 
synthetic to purely biological was used to extensively map the interaction between a70 
and AsiA. Specifically, three different approaches were applied: 1. Photo cross-linking 
of region 4.2 to AsiA, where six versions of region 4.2 peptide were synthesized, each 
containing a site-specific photo-reactive benzophenone cross-linker. 2. Combinatorial 
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chemistry, where the novel technique, Encoded Amino Acid Scanning (Camarero, 1998) 
was employed to generate an alanine scanning library of region 4.2. 3. Mutagenesis of 
the AsiA protein, to confirm the results from the two synthetic methods. What follows 
below is a detailed description of the design, synthesis and analysis of a70 region 4.2 
benzophenone cross-linker peptides (my contributions to this work), a summary of the 
other two approaches, and a discussion of the results that were published (Minakhin, 
2001). 
Design and Synthesis of a70 region 4.2 benzophenone cross-linker peptides 
Region 4.2 of E. coli a70 is both necessary and sufficient to bind T4 AsiA. This 
was previously determined using EPL (Severinov and Muir, 1998). Specifically, a 
semisynthetic version of a70 was found to bind AsiA in a Ni2+-NTA-agarose co-
immobilization assay, whereas a fragment of the protein lacking region 4.2 did not. 
Moreover, a synthetic histidine-tagged a70 fragment corresponding to region 4.2 only, 
was also able to bind wild type AsiA, demonstrating the interaction of these proteins. 
Therefore, to characterize the molecular contacts between a70 and AsiA, several region 
4.2 polypeptides were designed and synthesized containing the photoactivatable cross-
linker, benzophenone. Benzophenone was chosen for several reasons: It is activated at a 
wavelength that will avoid damaging proteins (350-360 nm); it does not decompose into 
an inactive compound if cross-linking is not achieved (Hermanson, 1996); finally, it is 
relatively small (277amu) and can be attached to the peptide backbone via a short spacer, 
thus limiting the distance between the cross-linker and the protein of interest. When 
benzophenone is activated with uv light it becomes a very reactive ketone radical 
intermediate that can react with C-H or N-H bonds to form stable covalent cross-links. If 
no covalent links are formed, the excited benzophenone species relaxes to the ground 
state, maintaining its binding and photoactivatable properties, and can then be recycled 
until a covalent modification is achieved. Thus, a benzophenone molecule has more than 
one chance to form a stable cross-link with the target protein. 
At the time this study was conducted, the structure of region 4.2 of E. coli a70 was 
unknown, however it was speculated to be similar to that of many other D N A binding 
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proteins, namely a helix-turn-helix (HTH) motif (Helmann, 1988; Kim, 1995). Thus, in 
deciding where to site-specifically incorporate the benzophenone cross-linker, a 
secondary structure prediction analysis was performed using the structure prediction 
program PHDsec. Also the sequence of a70 region 4.2 was traced through homologous 
H T H proteins using the H O M O L O G Y program in the Insightll package. In performing 
these structure prediction analyses, the goal was to predict the residues in region 4.2 that 
could potentially participate in informative cross-links; namely, those residues that are 
oriented toward the solvent phase and away from the hydrophobic core of the protein. 
Using this approach, six residues were identified that spanned region 4.2 and were 
predicted to be solvent exposed on the surface of the H T H motif. These residues are not 
conserved in other o factors, and are thus less likely to be required for the proper function 
of a70. The six residues are: Tyr571(20), Lys578(21), Arg586(22), Arg588(23), Lys593(24), 
and Lys597(25). These correspond to a benzophenone cross-linker at every 5.5 residues in 
region 4.2 (Figure 3.3-3). 
R5S6 
K578 
R588 K593 
Figure 3.3-3. Homology model of Region 4.2. The six residues in region 4.2 that will 
be replaced are indicated. 
Using optimized Boc-SPPS (Schnolzer, 1992), a wild-type version of a70 region 
4.2 (19) and six synthetic region 4.2 analogues (20-25), each containing a benzophenone 
cross-linker in the six positions identified above were synthesized. The six synthetic 
peptide analogues each contained a single amino acid substitution where the wild-type 
residue was replaced by L-diaminopropionic acid (DAPA). The benzophenone cross-
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Figure 3.3- 4. Introduction of benzophenone into a region 4.2 peptide by SPPS. 
linker was then introduced via an orthogonal protection strategy, which allowed the P-
amino group of the D A P A residue to be acylated with benzoylbenzoic acid. Figure 3.3-4 
depicts the SPPS procedure. E S M S and analytical HPLC confirmed the composition and 
purity of the peptides (Table 1 for E S M S analysis). 
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Table 1. The wildtype and modified a70 region 4.2 peptides synthesized are indicated 
along with their respective mass. 
Region 4.2 
Peptide 
wt4.2 (19) 
Tyr571 (20) 
Lys578 (21) 
Arg586 (22) 
Arg588 (23) 
Lys593 (24) 
Lys597 (25) 
Expected 
Mass (Da) 
4116.2 
4248.0 
4284.0 
4255.0 
4255.0 
4284.0 
4284.0 
Observed 
Mass (Da) 
4115.2 ±0.5 
4248.2 ±1.4 
4284.8 ±1.3 
4255.9 ±0.6 
4254.7 ±0.7 
4283.8 ±0.6 
4284.8 ±1.3 
Cross-linking analysis of the region 4.2 benzophenone constructs 
The purified a70 region 4.2 peptide analogues were combined with recombinant 
AsiA and irradiated with high intensity 355 nm laser light. After irradiation, the samples 
were analyzed by SDS-PAGE (Figure 3.3-5). A new band with increased electrophoretic 
mobility corresponding to a molecular weight of -14 kDa appeared in cross-linking 
reactions involving all of the o70region 4.2 peptides. For example, a cross-linked band 
was observed for the reaction involving AsiA and o70region 4.2 derivatized at the 
position corresponding to Lys593 (Figure 3.3-5A, lane 2). This band was absent from 
control reactions, that either contained AsiA or a70 region 4.2 peptide alone, or contained 
both interaction partners but were not irradiated with laser light (lanes 1, 3, and 4, 
correspondingly). It was concluded that the low mobility band is the result of a protein-
protein cross-link between the derivatized region 4.2 peptide and AsiA. This experiment 
was repeated for all six benzophenone region 4.2 peptide analogues and in all cases the 
results were the same. Representative data from these experiments where a70 region 4.2 
•r'7R S^ft 0^7 
peptides derivatized at the positions corresponding to Lys , Arg , and Lys are 
shown (Figure 3.3-5B, lanes 10,12, and 14). 
The protein-protein cross-link between the derivatized a70 region 4.2 peptides and 
AsiA was specific, since no cross-link was observed when reaction mixtures contained 
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myoglobin instead of A s i A (Figure 3.3-5A, lane 7 ) ; n o cross-link w a s observed w h e n 
underivatized a70 peptide (20) w a s used with A s i A (Figure 3.3-5A, lane 5); and addition 
of excess of wild-type a70 region 4.2 peptide (20) decreased the cross-link yield (Figure 
3.3-5A, lane 6). Thus, it was concluded that the interface of the o70-AsiA complex is 
extensive, with spatially separated derivatized region 4.2 amino acids either in direct 
contact, or close to A s i A in the complex. 
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.70 Figure3.3-5. Protein-protein cross-linking b e t w e e n derivatized a region 4.2 
70 peptides and AsiA. (A) a region 4.2 peptide containing benzophenone probe 
incorporated at position Lys593 was mixed with the indicated proteins in 20 fl of 
transcription buffer. Reactions were irradiated with 355 nm light from a laser source, and 
reaction products were resolved by SDS-PAGE and visualized by Coomassie staining. 
Lane 2 shows a high running band that corresponds to cross-linked product. This product 
is not present when derivatized region 4.2 peptide and AsiA are combined in the absence 
of uv light, see lane 4. Thus the high running band in lane 2 must be due to cross-linking 
of the two constructs. (B) Repeat of experiment in (A), this time using region 4.2 
•T7R SRS SQ7 
peptides derivatized at Lys , Arg , Lys . All derivatives peptides gave the same 
results as Lys593, i.e. protein-protein crosslinking is observed only when the peptides are 
combined with AsiA in the presence of uv light, see lanes 10, 12, and 14. 
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Combinatorial library and Mutagenesis results 
The result described above, namely, that the a70 region 4.2-AsiA interface 
involves interactions of multiple residues rather than a single key residue, was confirmed 
using a synthetic alanine scanning library of a70 region 4.2. Using the encoded amino 
acid scanning technique (Camarero, 1998), every residue in region 4.2 (residues 569-
599) was mutated to an alanine residue and the ability of the mutant to bind AsiA was 
tested using an AsiA affinity column. Alanine substitutions at 6 positions corresponding 
to a70 residues Thr569, Val576, He590, Lys593, Leu595 and Arg596 gave rise to the largest 
reduction of AsiA binding affinity. With the exception of the Thr569 and Val576 
substitutions, mutations that affected AsiA binding are clustered together in a short motif 
near the C-terminus of a70 region 4.2 (Minakhin, 2001) (Figure 3.3-6). Residues Lys593, 
Leu595 and Arg596 have been shown previously to not be involved in the interaction with 
D N A , but rather appear to participate in protein-protein interactions with several types of 
transcription activators (Lonetto, 1998). 
< < < 
co co r^  
0} O CD 
in ijO m 
-ice * 
<< 
COO) 
0>0> 
win 
-"DC .70 Figure 3.3-6. Relative affinities of the members of the a region 4.2 alanine library 
for binding AsiA to wild type. The ED50 values were calculated by competitive elution 
from the AsiA column with untagged wild-type peptide from two independent 
experiments. With the exception of the Thr569 and Val5 6 substitutions, mutations that 
affected AsiA binding are clustered together in a short motif with the C-terminal of 
region 4.2. 
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In order to identify the AsiA amino acid residues that interact with o70 region 4.2, 
five peptides, named Asil through Asi5, which correspond to AsiA amino acid residues 
1-20, 21-40, 41-60, 61-80, and 71-90 were synthesized. Each of these peptides was 
tested for the ability to inhibit a70-dependent transcription (Figure 3.3-7). 
AsiA ..,—— -— 90 aa 
1 -20 
Asi1 21 -40 
Asi2 41 -60 
Asi3 61 -80 
Asi4 71 -90 
Asi5 
Abortive 
Transcription 
Initiation —CpApU 
Figure 3.3-7. Inhibition of a70 transcription by AsiA peptides. Abortive transcription 
initiation was performed in the absence of AsiA (lane 1), in the presence of 0.5 p.M AsiA 
(lane 2), or in the presence of 25 \xM of the indicated AsiA peptides using the T7 Al 
promoter containing D N A fragments as a template, and C p A and [a- P]UTP as 
substrates. Reaction products were resolved on a 2 0 % polyacrylamide gel and visualized 
by autoradiography. As the gel indicates, it appears as if the first twenty amino acids are 
necessary for AsiA inhibiton of a70 dependent transcription. 
Asil inhibited transcription on the T7 Al promoter, while the other peptides had 
no effect. To further explore the notion that AsiA interacts with a70 through its N-
terminal 20 amino acid residues, three terminal recombinant deletions of cloned AsiA 
were constructed. The constructs, AsiAAN3, AsiAAN5, AsiAdN2°, and AsiAAC2° (indicating 
that the first N-terminal three, five, and twenty residues were removed, and the last C-
terminal twenty residues removed, respectively) were purified and their ability to inhibit 
<j70-dependent transcription from the T7 Al promoter was investigated. AsiAAN 
inhibited abortive transcription at levels that were similar to wild type (Figure 3.3-8, 
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lanes 1 and 2). AsiAAN5 and AsiAAC2° resulted in partial inhibition of transcription 
(Figure 3.3-8, lanes 3 and 5), while AsiAAN2° had little effect on transcription (Figure 3.3-
8, lane 4). Thus, it was concluded that the first 20 amino acids of AsiA are necessary and 
sufficient for binding and inhibiting transcription of o10(Minakhin, 2001). 
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Figure3.3-8. Analysis of recombinant AsiA deletion mutants. Abortive transcription 
initiation was performed using a70 dependent transcription in the absence of AsiA (lane 
6), or in the presence of 5-fold excess of the wild type (lane 1), or indicated mutant 
derivatives of AsiA (lane2-5). The T7 Al promoter containing D N A fragment was used 
as a template, and CpA and [a-32P] UTP as substrates. Reaction products were resolved 
on a 20 % polyacrylamidegel and visualized by auto radiography. As shown in the gel, 
the AsiA (-N20) mutant has no affect on transcription initiation (lane 4). 
Discussion of experimental results 
Combining the results obtained from the U V photo cross-linking experiments, 
alanine library, and AsiA deletion mutants described above, a model was proposed in 
which AsiA inhibits a70-dependent transcription in an indirect manner with several region 
4.2 residues contacting AsiA. Recent N M R structure studies of the bacteriophage T 4 
AsiA protein confirm the finding that C-terminal residues of region 4.2 identified by 
alanine scanning are involved in binding to AsiA (Lambert, 2001; Urbauer, 2002). 
However, they suggest that more than the first 20 amino acids of AsiA are involved in 
binding a70 (Urbauer, 2001). One reason for the discrepancy between these and our 
results could be that the assays are different. Urbauer and co-workers used an N M R 
76 
minimal chemical shift perturbation assay to probe the binding of AsiA to the C-terminus 
of a .In our work, an abortive initiation assay was used to test the function of the AsiA-
70 • • 
o mteraction. An abortive initiation assay measures more than the interaction of AsiA 
and a70, it also gauges the ability of this interaction to inhibit transcription. Perhaps, in 
the context of transcription initiation the a70 interactions with AsiA are shifted by the 
presence of core R N A P which a70 also binds. Thus it is possible that more than the first 
20 residues of AsiA are necessary for binding a70 when a70 is not in the context of core 
RNAP. 
Towards determining the influence of region 1.1 on the a70-AsiA interaction 
Design of the fluorescently labeled cr70 constructs 
To examine the influence of region 1.1 on the o70-AsiA interaction, several 
versions of a70 were synthesized. Using EPL, a strategy was devised to site-specifically 
label region 4.2 of a70 with a fluorescent probe, then using fluorescence spectroscopy, 
monitor the change in fluorescence of the probe as increasing concentrations of AsiA 
protein are titrated. Subsequent analysis of the fluorescence data would yield the K<i of 
the a70 AsiA interaction. If the inhibitory effect of region 1.1 observed in cr^by N M R 
also occurs in a70, then full length and a truncated version of the protein, missing region 
1.1, should yield slightly different K^ values for the a70 AsiA interaction. 
To this end, a70 region 4.2 peptides were synthesized with fluorophores site-
specifically incorporated at Lys578. This residue was selected based on results from the 
alanine scanning library experiment described above, which indicated that Lys578 is 
located outside the binding region of AsiA to a70 (Figure 3.3-6). Two different 
fluorophores were incorporated at Lys578: fluorescein or dansyl. These were chosen 
because they absorb at wavelengths that will not damage the protein (dansyl = 380 nm, 
fluorescein = 490 nm), and they have unique features that could be exploited. For 
example, dansyl intrinsic fluorescence is sensitive to environmental changes, and 
fluorescein fluorescence has a high quantum yield and the probe can be used in 
anisotropy measurements. 
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Two versions of the o70-VMA-intein-CBD fusion protein were constructed, a 
recombinant a70 containing the first 566 amino acids (a70i.566-VMA-intein-CBD (26)), 
and a truncated version of a70 missing region 1.1 (a70ioi-566-VMA-intein-CBD (27)). 
These constructs were then ligated to either the fluorescently labeled a70region 4.2 
peptides or a small model peptide, C G R A K G , labeled with a fluorescent probe. The 
model peptide was constructed to examine the recent finding that region 4.1 is involved 
in AsiA binding. Previously, only region 4.2 was believed to be responsible for AsiA 
binding (Severinov and Muir, 1998), however, it has recently been reported that region 
4.1 may also be involved (Urbauer, 2001). The two constructs, a70i.566-VMA-intein-
C B D (26) and a70ioi-566-VMA-intein-CBD (27), both terminate at region 4.1. In a display 
of the robust and versatile nature of EPL, the thioester formed during thiol cleavage of 
the intein fusion proteins was exploited to introduce a small model peptide, C G R A K G , 
labeled with a fluorescent probe, thus yielding a™i-566and o70ioi-566 labeled at region 4.1. 
Applying these 4.1 labeled constructs to the fluorescence assay would enable us to 
investigate if AsiA does indeed bind to region 4.1 in a70, and if this binding is affected by 
region 1.1. Figure 3.3-9 depicts the EPL synthesis strategy for the fluorescently labeled 
a constructs. 
i.) Clone gene into intein vector 
-Intein-CBD 
a70-1.1 -4.2 
r ii.) Cleave in presence of region 4.2or model peptide with 
fluorescent probe 
A 
Cys 
~\ 
A 
Full length a70 with probe Truncated o70with probe 
F i g u r e 3.3-9. Synthesis strategy of fluorescently labeled a70 constructs b y E P L 
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Synthesis of the fluorescently labeled cr70 constructs 
T h e a70 region 4.2 peptides labeled site-specifically at Lys578 with a fluorescein 
(region 4.2-fl (28)) or dansyl (region 4.2-dansyl (29)) fluorophore were synthesized in a 
manner similar to that of the o70 region 4.2 benzophenone peptides described above. In 
this instance, to attach the fluorescent probe, the D A P A mutant at Lys578 was acylated 
with either a fluorescein succinimidyl ester or a dansyl chloride. The small model 
peptide C G R A K G was synthesized by standard Boc SPPS and acylated at the Lys residue 
with either a fluorescein (model-fl (30)) or dansyl (model-dansyl (31)) probe. The 
composition and purity of all peptides were confirmed by analytical H P L C and E S M S . 
Table 2. List of chaotropic and organic solvents used in o E P L trial ligation buffers 
Chaotropic and organic solvents used in 
a70 E P L trial ligation reactions 
Guanidine Hydrochloride 
Urea 
Dimethyl sulfoxide 
Acteonitrile/ Water 
Triton X detergent 
Table 3: M A L D I - T O F M S characterization of a ligation products 
Fluorescently labeled a 
ligation constructs 
ys~ 
a70 ,.566-4.2^1(32) 
a70,o,-566-4.2-Fl(33) 
a70,.566-model-Fl(35) 
170" 
101 .566 -model-Fl (36) 
Expected Mass 
(Da) 
69178.1 
58 261.2 
65696.1 
54799.2 
Observed Mass 
(Da) 
69112 + 86.6 
58258.2+1.8 
65730 + 42.0 
54886.2 + 97.4 
Note: a70 constructs (34) and (37) do not ionize under MALDI-TOF M S . 
In a manner similar to that reported by Severinov and Muir (Severinov and Muir, 
1998), standard molecular biology procedures were used to clone the o70i.566 and a70ioi-566 
fragments into the commercially available VMA-intein plasmid. Expression of the 
plasmids in E.coli BL21 cells gave the desired fusion proteins, a7Y566-VMA-intein-CBD 
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(26) and a70ioi-566-VMA-intein-CBD (27). Following cell lysis, the fusion proteins were 
purified from the soluble fraction by affinity chromatography on chitin beads. 
The four fluorescent peptides, region 4.2-fl (28), region 4.2-dansyl (29), model-fl 
(30) and model-dansyl (31), were then linked to the recombinant constructs aTOi-566-
intein-CBD (26) and a70ioi-566-intein-CBD (27) using EPL. The ligation reactions 
involving peptides (28) and (29) were complicated by insolubility of these peptides in 
standard E P L buffer (0.2 M sodium phosphate, 0.2 M NaCl, p H 7.2). Due to this 
solubility issue it was explored whether E P L could be performed in the presence of 
different chaotropes and organic solvents (see Table 2 for list of conditions explored). 
Satisfactory results were eventually obtained by first dissolving peptides (28) or (29) in 
H2O/0.1% T F A , then flash diluting the peptide into a slurry of immobilized fusion 
protein (26) or (27) in E P L buffer containing 3 % ethanethiol and l O O m M 
mercaptoethanesulfonic acid. Figure 3.3-10 shows a representative S D S - P A G E analysis 
of E P L ligation reactions between fusion proteins (26) and (27) and fluorescent peptides 
(28) and (29), indicating the appearance of bands corresponding to the desired products 
a70,.566-4.2-fl (32), o70,oi-566-4.2-fl (33) and a70,0.-566-4.2-dansyl (34). 
supernatant supernatant begds 
3 4 5 6 7 8 9 
Coomassie stain Fluorescent-image 
Figure 3.3-10. SDS-PAGE analysis of a70 ligation reactions. 20ml of supernatant and 
chitin beads from crude EPL ligation reactions of (32), (33) or (34) with (28) or (29) were 
loaded on to 4-20% polyacrylamide gel and visualized by coomassie stain and fluorescent 
imaging. The lanes of the gel are as indicated: 
l .j70 wild type. 
{ 2 . Full lengfli a70 with a fluorescein pube. 
3. Rill length a70 with a fluorecsein pobe. 
4. o70Aiegion1.1 with a fluorescein pobe. 
5. a70 a region 1.1 wifln a dans yl pobe. 
{ 6 . Chiti beads of reaction in lane 2. 
7. Chitin beads of reaction in lane 3. 
8. Chitin bsadsotreaclion inlane 4. 
9. Chitin beads of reaction in lane 5 
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The gel was visualized by coomassie staining and fluorescent imaging (Figure 
3.3-10). Lanes 2-5 represent the ligation supernatant, and lanes 6-9 the chitin beads of 
the fusion proteins (26) or (27). As shown in lanes 6-9, much of the ligation product 
remained bound to the chitin beads, however, this product could be removed by washing 
the beads with standard EPL buffer. H P L C and MALDI-TOF mass spectrometry 
analysis confirmed the formation of the ligation products (Figure 3.3-11). Similar 
ligations were conducted with model peptides (30) and (31) to give the desired ligation 
products, see Table 3 for MALDI-TOF M S characterization of the a70 ligation products. 
Since comparison of several fluorescein and dansyl constructs indicated that fluorescein 
labeled constructs allowed for better characterization of the protein, the a70i-566-4.2-
dansyl was not generated. MALDI-TOF analysis revealed that in each of the a70 ligation 
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70 Figure 3.3-11. R P - H P L C and M A L D I - T O F M S analysis of fluorescent a 
constructs. (A.) RP-HPLC (1) and MALDI-TOF M S (2) of crude EPL reaction: a70,.566 
+ 4.2 fluorescein peptide. RP- HPLC gradient is 0-73% B. over 30 min. [Observed mass 
=69,112 ± 86.6 Da; expected mass (average isotopic mass) = 69,178.1 Da]. (B.) RP-
H P L C (1) and MALDI-TOF M S (2) of crude EPL reaction: o 7010i-566+ 4.2 fluorescein 
peptide. RP- H P L C gradient is 0-73% B. over 30 min. [Observed mass =58,258.2 ± 1.8 
Da; expected mass (average isotopic mass) = 58,261.2 Da]. MALDI-TOF M S anaylsis 
indicates two species present in ligation product peak from RP-HPLC, the desired 
ligation product and a hydrolysis product (*). 
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Figure 3.3-12. Anion exchange purification of fluorescently labeled a70 E P L 
construct (32). (A) F P L C trace of crude E P L ligation supernatant from reaction of a70-
model-Fl construct (36). The ligation supernatant was purified by anion exchange (Q 
column) using 0.1-1M NaCl, 3 0 m M sodium phosphate buffer, p H 7.2. The indicates 
pure ligation product (36). (B) M A L D I - T O F M S analysis of starred peak from F P L C 
trace. [Observed mass = 65,730 + 42 Da; expected mass (average isotopic mass) = 
65,696.1 Da]. M A L D I - T O F indicates a single species, the desired ligation product (32). 
reactions both the desired ligation product and a hydrolysis product were present (Figure 
3.3-11). 
Purification by anieschange using a sepharose stationary phase allowed these 
products to be resolved to a homogeneous ligation product (Figure 3.3-12). The purified 
protein was then exchanged to fluorescence buffer (0.1M sodium phosphate, 50 m M 
NaCl, p H 7.2) by gel filtration. This additional buffer exchange step significantly 
diminished the yield of the a70 constructs. Therefore, to increase yields the anion 
exchange step was later omitted from the purification process and only gel filtration was 
used. Gel filtration was effective in separating the a70 constructs from unreacted peptide, 
but it did not separate the hydrolysis a70 product from the desired a70 ligation product 
(Figure 3.3-13). While it is always desirable to use a homogeneous sample for 
biochemical/biophysical studies, here the contaminant protein is non-fluorescent and thus 
transparent to our binding assay. 
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Full length o70-FI 
Region4.2-fl peptide 
B . Coomassie stain Fluorescent-image 
X Full length o70-^ 
Figure 3.3-13. Gel filtration purification of a70 EPL construct (32). (A) Gel filtration 
H P L C trace of crude ligation reaction of o 70|.566-VMA-intein-CBD (26) and region 4.2-
FL (28) using Zorbax gel filtration GF-250 column with running buffer 50 m M sodium 
phosphate, 0.1M NaCl pH 7.2 over 30 min. (B) SDS-PAGE analysis of the full-length a 
7°i-566-Fl product (32) collected from gel filtration purification. The gel was visualized 
by coomasie stain and fluorescent imaging. No unreacted 4.2 peptide (28) is present. 
Spectroscopic analysis revealed that the labeled a70 constructs were fluorescent 
(Figure 3.3-14). Thus a semisynthetic route to fluorescent a70 analogues that may be 
useful for examining the influence of region 1.1 on the a70 AsiA interaction was 
successfully developed. As noted above, several technical problems had to be resolved 
during the course of this work. These have now been addressed (which allowed the 
scope of EPL to be extended), however, due to time constraints brought on by these 
problems, the fluorescence binding assays on AsiA were unable to be performed. 
However, a robust semisynthetic route to a70 analogues is now in place, and this impor-
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Figure 3.3-14. Fluorescence emission spectrum of a70 construct (32). The a 70 
construct (32) labeled with fluorescein was excited at 490nm (Fl absorption) and 
fluorescence emission was monitored from 500-600nm. (32) (5nM) was dissolved in 200 
uL of 0.1M sodium phosphate, 5 0 m M NaCl, pH 7.2. Emission maximum at 520nm is 
characteristic of a fluorescein containing compound. 
tant a70 function will be addressable in future studies within the Muir group. 
Concluding remarks on the incorporation of biophysical and biochemical 
probes into a70 - significance to EPL development 
This work illustrates the enormous potential of expressed protein ligation for 
exploring the mechanism and regulation of complex biomolecular machines like E. coli 
a70. Specifically, the molecular nature of AsiA inhibition of E. coli a70-dependent 
transcription was investigated, and the constructs for determining the influence of region 
1.1 the a70-AsiA interaction were synthesized. 
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Using a combination of protein-protein photo cross-linking, combinatorial peptide 
chemistry and mutational analysis to extensively map the a70-AsiA interactions, it was 
determined that AsiA inhibits E.coli a70-dependent transcription in an indirect manner. 
AsiA appears to cover most of the region 4.2 surface, including the putative D N A 
binding helix, but does not directly interact with the amino acids involved in binding the 
of -35 promoter D N A sequence. It was also determined that the first 20 amino acids of 
AsiA were sufficient for its binding to o70. While it is possible that other residues within 
AsiA are involved in the interaction (Lambert, 2001; Urbauer, 2001; Urbauer, 2002), 
these interactions are clearly dispensable for the transcription inhibition activity of AsiA. 
Several a70 constructs site-specifically labeled with a fluorescein or dansyl 
fluorescent probe were synthesized using EPL. These constructs could be used in future 
studies to investigate the influence of region 1.1 on the a70-AsiA interactions. Due to the 
insoluble nature of region 4.2, several chaotropic and organic solvents were employed 
during the E P L ligation reactions, further outlining the range of this methodology. 
Furthermore, the successful synthesis of the 70 kDa a70 subunit, all but eliminates the 
size barrier issue that affected other protein synthesis techniques, demonstrating that E P L 
can be used to generate large macromolecules for use in structure-function analysis 
experiments. 
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Chapter 4: Conclusion 
"All technical evolution has a fundamental behavior pattern. First there is scientific 
discovery of a generalized principle... Next comes objective employment of that principle 
in a special case invention. Next the invention is reduced to practice... If successful as a 
tool of society, the invention is used in bigger, swifter, and everyday ways..." 
-R. Buckminster Fuller(Fw//er, 2002) 
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S u m m a r y of thesis work 
The goal of this thesis was to illustrate the development and application of the 
protein semi-synthesis technique Expressed Protein Ligation (EPL) as a readily 
accessible and effective tool for the incorporation of unnatural amino acids and physical 
probes into proteins. The scope and versatility of EPL was demonstrated using three 
distinct applications. 
In the first application, section 3.1, a successful strategy was developed for the 
site-specific incorporation of fluorophores into proteins. Using AM-SH3 as a model 
protein, a method was devised for site-specifically incorporating fluorescein and 
rhodamine fluorophores into a contiguous receptor-ligand designed to act as a biosensor 
for macromolecular interactions. The biosensor was not realized, but what is striking 
about this example, is that it identified a method for incorporating, not only one, but two 
fluorophores into the protein at the specific locations of interest. In addition, our work 
with the Abl-SH3 domain demonstrated the robust nature of the EPL reaction to organic 
and chaotropic solvents. Specifically, EPL can be preformed in the presence of 1 0 % 
D M S O and up to 2 M concentrations of GdmCl (Ayers et al, 1999). The tolerance of 
EPL to these agents has important implications when dealing with poorly soluble 
synthetic peptides in ligation reactions, and has been used routinely in the Muir lab to aid 
in the successful synthesis of a number of protein targets (Blaschke, 2000; Camarero, 
2002; Cotton, 2000; Valiyaveetil, 2002). 
In the second application, section 3.2, a general strategy was developed to site-
specifically introduce phospho-amino acids into proteins for analysis of signal 
transduction pathways. Using the transforming growth factor p receptor I (T(3R-I) as a 
model, the effects of phosphorylation on the activity of the kinase domain was 
investigated. To this end, a tetra-phosphorylated peptide "thioester was synthesized by 
Fmoc SPPS. Significantly, this was the first example of the chemical synthesis of a 
phosphopeptide "thioester, and new synthetic methodology was implemented for this 
purpose. The peptide "thioester was then successfully ligated to the N-terminus of the 
kinase domain of TJ3R-I. Initially, EPL was described as a semi-synthesis strategy for 
ligating the C-terminus of recombinant proteins to the N-terminus of synthetic constructs 
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(Evans et al, 1998; Muir et al, 1998; Severinov and Muir, 1998), however, with this 
application, it has been demonstrated that EPL can also be used at ligate the N-terminus 
of recombinant proteins to the C-terminus of synthetic constructs. This achievement 
broadened the range of the EPL technique. Also, the ability to obtain a homogeneous 
preparation of tetra-phosphorylated TpR-I allowed the level to which 
hyperphosphorylation activates the kinase to be quantified for the first time. As a result, 
a model was suggested in which the phosphorylated GS region may activate the receptor 
in a positive manner (Huse, 2000). These findings could not have been achieved with out 
EPL. Thus, it has been effectively demonstrated that EPL is a powerful tool for 
investigating the effects of post-translational modifications on cellular signaling proteins. 
In the third and final application, section 3.3, the enormous potential of expressed 
protein ligation for exploring the mechanism and regulation of complex macromolecular 
machines was illustrated. Several versions of E. coli a70 were designed and synthesized 
in order to map and quantify the inhibition of a70 transcription initiation. Using a 
combination of genetic, biochemical, synthetic and combinatorial chemical approaches it 
was determined that the AsiA protein contacts several amino acids in region 4.2, and 
completely occludes the DNA-binding surface of region 4.2, thus acting in an indirect 
manner to inhibit a70 dependent transcription (Minakhin, 2001). In an effort to examine 
the influence of region 1.1 on the Kd of the a70 AsiA interaction, several versions of o70 
(full length, truncated A region 1.1, and truncated A region 4.2) containing a fluorescein 
or dansyl fluorophore were synthesized. Due to the insoluble nature of region 4.2, 
several chaotropes and organic solvents were examined for their use in EPL reactions 
(see Table 3). These conditions further define the scope of the EPL method. The 
successful synthesis of the fluorescently labeled 70 kDa o70 constructs illustrates the use 
of EPL as a tool for engineering large proteins. 
In summary, expressed protein ligation was successfully developed and applied to 
the semi-synthesis of three very distinct macromolecules, ranging in size (from 9 kDa 
(Abl-SH3) to 70 kDa (o70)) and function. These achievements effectively demonstrate 
that EPL is a powerful tool for chemically manipulating proteins by allowing the 
introduction of a host of alterations that range from biochemical and biophysical probes 
to post-translational modifications. In 1997, when EPL was initially conceived, the 
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impact of the technology could not be predicted. In 2002, just five years later, EPL has 
been established as a potent tool for engineering proteins. A review of the literature 
indicates that over forty different proteins have been studied by EPL to date (Table 4), 
with multiple semi-synthetic analogues of the same protein having been prepared in 
several instances. This analysis also reveals that the number of EPL applications is 
increasing rapidly each year, from half a dozen reports in the first year, to over 30 in the 
last 12 months. The work carried out this thesis has helped to bring about this 
transformation by providing the fundamental technical guidelines with which to apply 
EPL to diverse systems. This has allowed us to go from the proposed applications 
depicted in Figure 1.6 to the commanding list of successful applications shown in Table 
4. 
Concluding remarks about the future of E P L 
Understanding protein function is at the heart of experimental biology. This 
requires a full description of a protein's post-translational modifications and how these 
affect intrinsic function and three-dimensional structure, as well as investigations of 
protein-protein interactions. To achieve this at the level of a proteome is a heart-stopping 
proposition, yet the assembly of this encyclopedia must be one of the long-term goals of 
biology. The magnitude of this task is fueling considerable interest in the development of 
new technologies that allow the acquisition of information regarding protein function to 
be acquired at an accelerated rate relative to traditional genetic or biochemical 
approaches. The emergence of dynamic new fields such as Proteomics, Structural 
Genomics, Bioinformatics and Chemical Biology illustrates how this problem is 
attracting the attention of researchers from a broad range of disciplines and expressed 
protein ligation is poised to make a huge impact in these emerging fields. 
EPL is the chemical protein engineering equivalent to a jack-of-all-trades. 
Presented in Figure 4.1 are the different EPL strategies for synthesizing a target protein. 
The technology has advanced to the point where the original description of EPL, a semi-
synthetic strategy for attaching synthetic constructs to the C-terminus of recombinantly 
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expressed proteins (Figure 4.1, ligation product (i)), is only one of three possible 
outcomes that can be achieved. Currently E P L can be used to combine t w o fragments of 
a recombinant protein (Figure 4.1, ligation product (ii)), or to attach a synthetic construct 
to the N-terminus of a recombinantly expressed protein (Figure 4.1, ligation product 
(iii)). Although, not depicted, it is also possible to cyclize a protein and insert synthetic 
fragments into a protein's core using E P L . This versatility m a k e s E P L a potent tool for 
addressing proteome type questions. In fact, recent publications have examined the use 
of expressed protein ligation to the generation of proteins for use in protein microarrays 
(Lesaichere, 2 0 0 2 ; Tolbert, 2002). T h e ease and applicability of the E P L technology to 
protein engineering suggests that it will be used increasingly in m o r e areas of biology. 
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Figure 4.1. C u r r e n t E P L ligation strategies, (i) Ligation of a synthetic construct to the 
C-terminus of a recombinant fragment, (ii) Ligation of two recombinant fragments, (iii) 
Ligation of a synthetic construct to the N-terminus of a recombinant protein. 
Herein, I have described in vitro applications of E P L . This is scratching the 
surface of E P L ' s abilities, for as the technology improves for introducing semi-synthetic 
proteins into cells (Morris, 2 0 0 1 ; Schwarze, 2 0 0 0 ) one can only anticipate seeing an 
increase in the n u m b e r of in vivo studies using proteins created b y expressed protein 
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ligation. Such an application would truly signal the dawning of a new millennium in the 
field of chemical protein engineering. 
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Table 4. Proteins engineered using EPL. 
Protein 
AP-1 
c-Abl 
Calcitonin 
c-Crk 
Csk 
GlyCAM 
Hedgehog 
Hpal 
KcsA 
p-lactamase 
Leptin 
MBP 
McbA 
P21Max 
Rab 
RNAP p' 
RNase A 
SHP-2 
a70 
SigmaA 
Smad2 
Smad3 
Src 
STAT1 
TpR-I 
T4 DNA ligase 
T7RNAP 
Thioredoxin 
ThiS 
VEGF 
Size 
70 
160 
32 
304, 56 
450 
77 
-170 
254 
135 
278 
146 
395 
40 
101 
203 
1407 
124 
568 
613 
400 
221,462 
125,425 
441 
713 
303 
487 
887 
135 
66 
110 
Manipulation 
Fe-EDTA probe. 
Segmental isotopic labeling, 
fluorescent probe. 
C-terminal amidation. 
Fluorescent probes, backbone 
cyclization. 
Fluorescent probes. 
Carbohydrate. 
Lipidation. 
Semi-synthesis. 
Semi-synthesis. 
Backbone cyclization. 
Semi-synthesis. 
Various C-terminal 
moditications. 
Unnatural amino acids. 
Phosphorylation. 
Fluorescent probe. 
Fluorescent probe. 
Semi-synthesis and 
Selenocysteine ligation. 
Phosphonate. 
Semi-synthesis. 
Segmental labeling. 
Phosphorylatio.n 
Phosphorylation. 
Tyrosine analogs. 
Fluorescent probe. 
Phosphorylation. 
Semi-synthesis. 
C-terminal modifications. 
Backbone cyclization, 
polymeric versions prepared. 
Semi-Synthesis. 
C-terminal modifications. 
References 
(Chytil. M, 1998; Erlandson et al., 
1996) 
(Cotton et al., 1999; Xu et al., 
1999) 
(Cottinqham, 2001) 
(Camarero, 1999; Camarero, 2001, 
Camarero, 2001; Cotton, 2000, 
Hofmann, 2001) 
(Muir etal., 1998) 
(Macmillan, 2000) 
(Porter, 1996; Taylor, 2001) 
(Evans et al., 1998) 
F. Valiyaveetil, T W M Unpublished 
(Iwai, 1999) 
E. Asilmaz, J. Friedman, 1. Giriat, 
T. W. Muir, Unpublished 
(Chongetal., 1997; Tolbert, 2000) 
(Roy, 1999) 
(Kawakami, 2001) 
(lakovenko, 2000) 
(Mukhopadhyay, 2001) 
(Evans etal., 1998; Hondal, 2001) 
(Lu, 2001) 
(Severinov and Muir, 1998) 
(Camarero, 2002) 
(Huse, 2001) 
(Huse, 2001) 
(Wang, 2001) 
Y. Lui, TWM, Unpublished 
(Flavell, 2002; Huse, 2000) 
(Evans Jr. etal., 1999) 
(Lykke-Andersen, 1998) 
(Evans, 1999) 
(Kinsland, 1998) 
R. Flavell, 1. Giriat, T.W. Muir, 
Unpublished 
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"It has all been very interesting and rewarding, and the opportunity of a lifetime. But 
now it is time to return to reality and resume my [life] because so many things have yet to 
be done." 
—Bruce Merrifield on returning to normalcy after his Nobel Prize publicity tour 
(Merrifield, 1993). 
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Chemical Biology. 
Biophysical Chemistry. 
Introduction to Protein Structure. 
Advanced Organic Chemistry (Columbia University). 
The Application of N M R Spectroscopy to Proteins (Columbia University). 
Cell Biology. 
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Huse, M., Holford, M . N., Kuriyan, J., Muir, T. W . (2000) Semisynthesis of 
hyperphosphorylated type I TGFb receptor: Adressing the mechanism of kinase 
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